Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal English
Coverage 121,640 Raw stories ingested 13,584 rewritten in CS_CZ • 0 to rewrite (last 2 days).
Agents 7 waiting Pipeline agents
  • FMP Stock News Fetch every minute 42s ago
  • FMP Forex News Fetch every 5 min 2m ago
  • CoinGecko News Fetch every 5 min 2m ago
  • FIO Stock News Fetch every 10 min 1m ago
  • Patria Stock News Fetch every 10 min 1m ago
  • Editorial rewrite Rewrite every minute 42s ago
  • Asset sync Assets every 1 hour 41m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Clear
Details Date Content Source
2026-07-14 16:19 27d ago
2026-07-14 10:01 27d ago
Deere & Company (DE) is Attracting Investor Attention: Here is What You Should Know
DE Deere & Co
FMP Stock News
Original source text
Deere (DE - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this agricultural equipment manufacturer have returned +1.8% over the past month versus the Zacks S&P 500 composite's +1.3% change. The Zacks Manufacturing - Farm Equipment industry, to which Deere belongs, has gained 1.2% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Deere is expected to post earnings of $4.82 per share for the current quarter, representing a year-over-year change of +1.5%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.1%.

For the current fiscal year, the consensus earnings estimate of $18.13 points to a change of -2% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $22.76 indicates a change of +25.5% from what Deere is expected to report a year ago. Over the past month, the estimate has changed -0.2%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Deere is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Deere, the consensus sales estimate for the current quarter of $10.83 billion indicates a year-over-year change of +4.6%. For the current and next fiscal years, $41.41 billion and $44.96 billion estimates indicate +6.4% and +8.6% changes, respectively.

Last Reported Results and Surprise HistoryDeere reported revenues of $11.78 billion in the last reported quarter, representing a year-over-year change of +5.4%. EPS of $6.55 for the same period compares with $6.64 a year ago.

Compared to the Zacks Consensus Estimate of $11.44 billion, the reported revenues represent a surprise of +2.98%. The EPS surprise was +12.74%.

Over the last four quarters, Deere surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Deere is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Deere. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
2026-07-14 16:19 27d ago
2026-07-14 09:57 27d ago
‘Being Hated Is Not Good for Business’: Mark Cuban’s $130 Billion Warning for AI Companies
ORCL Oracle Corp
FMP Stock News
Original source text
In a single quarter, communities blocked or delayed at least 75 AI data center projects worth roughly $130 billion. That figure, from Data Center Watch’s Q1 2026 report, is the highest quarterly total of disrupted data center developments on record. Mark Cuban’s read on why is blunt: it has nothing to do with data centers.

“It’s time for everyone to realize that the fight against data centers has nothing to do with data centers,” Cuban wrote on X on June 25, 2026. “They have become a proxy for the hate towards AI and the concentration and accumulation of wealth it’s creating.” His conclusion landed harder: “One thing I have learned is being hated is not good for business.”

The John Galt Problem Cuban argues the AI industry has already lost the public relations fight by talking instead of listening. “The big LLMs have lost the PR battle. Why? Because they all suck at putting people first. They have an SV attitude that makes them all think they are John Galt saving the world.” The reference, to Ayn Rand’s hero who expects the world’s gratitude for his innovations, cuts sharply. Silicon Valley spent years telling towns AI will change everything, when it should have asked what they need. Cuban’s view: “It’s too late” to sell the benefits of AI, and only material community support remains.

Why People Are Angry The anger has a concrete source: jobs. US employers announced just over 97,000 job cuts in May 2026, citing AI as the primary reason for almost 40%, per Challenger, Gray & Christmas, escalating from 7% of cuts in January to roughly 40% by May. “AI is now the leading reason companies give for cutting jobs,” said Andy Challenger. Oracle acknowledged AI cost 21,000 jobs at the company in 2026, per Forbes. On the same morning as Cuban’s post, Nobel laureate Paul Krugman argued on his Substack that AI companies “only belatedly realized that declaring that your technology will destroy jobs is not a great marketing strategy.”

Scale of Opposition Gallup (May 2026) found 71% of Americans oppose AI data centers near their communities, nearly half strongly, citing power and water use, pollution, noise, and rising utility costs. Morning Consult found support for banning construction near communities rose from 37% to 41% in a single month, with heaviest opposition in the Midwest and South. Prediction markets price regulatory risk directly: Polymarket traders assign a 36.5% probability that a US state enacts a data center moratorium by year-end, with New York’s Responsible Data Center Development Act awaiting Governor Hochul’s signature.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Microsoft didn't make the cut. Grab the names FREE today.

Cuban’s Prescription Cuban remains bullish on AI, saying he is “a believer there will be net gains in a few years.” His fixes: a community tour asking towns what they need (“You will need to do what they ask”); direct meetings with artists and creative unions in Los Angeles and New York, since “Every creative I know is TERRIFIED about what AI will do to their profession”; and funding community programs at scale, because “Billions of dollars is a lot of money across towns and city programs. Across the major LLMs, it’s a cost of doing business.” He opposes paid celebrity endorsements and political spending.

The Pushback Not everyone accepts the “proxy for hate” framing. A widely shared reply cited constant noise, light pollution, and falling property values from facilities running around the clock. Cuban’s retort: “Where was this fight against the CHIPS Act?” Columbia Business School’s Daniel Keum cautioned that companies blaming AI for layoffs “doesn’t necessarily mean that’s actually why those layoffs happened.”

Investing Implications The $130 billion in stranded or delayed projects is capital that is not building anything. Every hyperscaler racing to expand carries permitting and community risk: Meta (NASDAQ:META | META Price Prediction) raised 2026 capex guidance to $125 to $145 billion; Microsoft (NASDAQ:MSFT) is roughly doubling its data center footprint over the next two years; Alphabet (NASDAQ:GOOGL) guided $180 billion to $190 billion with a “significant” further increase planned for 2027; Amazon (NASDAQ:AMZN) posted $43.2 billion in Q1 cash capex; and Oracle (NYSE:ORCL) burned through $55.663 billion of FY2026 capex against negative free cash flow of $23.686 billion (see the Q4 filing). Oracle shares have fallen 29.47% over the past month, a reminder that markets are repricing capex risk. The Wyoming contamination incident tied to a Zuckerberg-backed facility drew congressional scrutiny and a broader suspension of operations, showing community hostility carries real cost. With 58% of Americans blaming data centers for rising electricity bills and AI capex scaling toward $700 billion a year, community benefit agreements are becoming standard.

Cuban’s closing line was direct: given the power and capacity the industry needs, if AI companies do not treat everyday people with respect, they will fall far short of the capacity their businesses require.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Microsoft didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.
2026-07-14 16:19 27d ago
2026-07-14 11:00 27d ago
Microsoft vs Oracle: One Thriving, One Burning Cash
ORCL Oracle Corp
FMP Stock News
Original source text
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Mariakray / iStock Editorial via Getty Images

Microsoft (NASDAQ: MSFT | MSFT Price Prediction) and Oracle (NYSE: ORCL) both posted AI-driven cloud numbers, yet the market rewarded one and punished the other.

Microsoft’s Q3 FY2026 report on April 29, 2026 looked like a cash machine humming along. Oracle’s Q4 FY2026 report on June 10, 2026 looked like a company betting the balance sheet on AI infrastructure.

Azure Prints Cash. Oracle Prints Backlog. Microsoft’s quarter felt boringly good. Revenue reached $82.886 billion, up 18.3% year over year, and EPS came in at $4.27 versus $4.0706 expected, the fourth consecutive beat. Intelligent Cloud grew to $34.681 billion (+30%), with Azure and other cloud services up 40%.

Satya Nadella told investors “AI business surpassed an annual revenue run rate of $37 billion, up 123% year-over-year.” Commercial RPO climbed to $627 billion, nearly doubling. Microsoft funded its $30.876 billion capex quarter out of $46.679 billion of operating cash flow.

Oracle’s story runs harder and hotter. Cloud infrastructure grew 93% to $5.787 billion, and total cloud is now 52% of revenue, up from 43% a year ago. RPO exploded to $638 billion, up 363%, though $75 billion is tied to prepaid or customer-supplied GPU arrangements.

Software license revenue slipped 6%, a reminder of the shrinking legacy base. The price of that pivot shows up in full-year capex of $55.663 billion and free cash flow of negative $23.686 billion.

Two AI Bets, Two Balance Sheets Microsoft spreads chips across Microsoft 365, LinkedIn, Dynamics, Windows, and Xbox while tripling down on AI capex.

July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.

Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.

With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.

Oracle pursues something narrower and braver. Co-CEO Clay Magouyrk framed the strategy plainly: “We are committed to Cloud Neutrality because we believe that our customers should be able to run their Oracle databases in any cloud they choose.” That is why the Multicloud AI Database jumped 404% in Q4, embedding Oracle inside Amazon, Google, and Microsoft datacenters.

Lens Microsoft Oracle Core Bet Agentic computing across a broad stack AI infrastructure and multicloud database Funding Model Self-funded from operating cash ~$40B debt and equity raise planned in FY2027 Key Vulnerability OpenAI dependence, capex payback Negative FCF, large-deal concentration Microsoft is down 9.08% since its April 29 report, while Oracle collapsed 29.47% in the month after June 10. Skeptics noticed the $218.703 billion in total liabilities.

The Next Test Is Whether the Backlog Converts Oracle guided FY2027 revenue to $90 billion with non-GAAP EPS of $8.05, and Q1 cloud growth of 58% to 64%. Keep an eye on whether that RPO becomes recognized revenue on schedule, because equity issuance and $124 billion in existing debt leave little margin for slippage.

For Microsoft, the tell will be Azure sustaining 40% growth as the $250 billion incremental OpenAI Azure commitment begins to flow. Investors curious about how these bets fit into a wider AI portfolio can look at the AI Boom Seven framework.

Why I Lean Toward Microsoft Right Now, With One Caveat If I had to pick today, I would lean Microsoft. Trading at a forward P/E near 20 with 46.3% operating margins, the risk profile fits how I invest: durable cash flow funding the AI buildout.

Oracle’s growth is more thrilling on paper, and the PEG ratio of 0.795 looks tempting. But I want to see one clean quarter of positive free cash flow before I trust the pivot. If you are a turnaround investor comfortable with leverage and volatility, Oracle offers real upside from $140.64. I would rather own the compounder that already knows how to print cash.

Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.

Over 50,000 people already have, along with global giants like General Motors and POSCO.

Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.

Contact [email protected] for any questions or corrections.
2026-07-14 16:19 27d ago
2026-07-14 11:17 27d ago
Oracle to pay dividends next week; Here's how much 100 ORCL shares will earn
ORCL Oracle Corp
FMP Stock News
Original source text
Oracle (NYSE: ORCL) is set to pay its quarterly dividend next week, on Friday, July 24, rewarding investors with $0.5 per share.

According to the technology giant’s press release, investors as of July 10 will be eligible for the payment, which remains unchanged from the previous two quarters.

Going by the numbers, 100 ORCL shares will net precisely $50 in quarterly dividends next week.

Oracle dividend calendar. Source: Oracle.com If the payment remains unchanged in the next quarter, investors will receive $200 in annual dividends this year. 

However, looking at historical trends, a dividend increase is likely, considering that the company has increased its dividends every year since it began distributing them, with the exception of 2013, when the payout was nearly 43% lower compared to 2012, as per DivvyDiary calendar.

Oracle stock dividend profile  Currently, Oracle has a forward dividend yield (FWD) of 1.53%, which is noticeably higher than the sector average of 1.37%. On the other hand, its payout ratio is 18.34, versus the industry 27%.

It also has an annual payout (FWD) of $2, and it pays dividends on a quarterly basis: in January, April, July, and October. The stock has an average price recovery of 7.4 days

While the figures are overall positive, the stock itself has suffered quite a lot this year. For context, an investor who placed $1,000 into Oracle at the beginning of 2026 would have seen the investment generate just about $6.6 in dividends, and they would have recorded a total loss of roughly $335.

In other words, in just over two quarters, the investment would have been worth approximately $665, representing a total loss of 33.5%. On an annualized basis, the investment recorded a compound annual growth rate (CAGR) of -53.66%, highlighting the magnitude of the year-to-date decline.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
2026-07-14 16:19 27d ago
2026-07-14 11:54 27d ago
What's Going On with Oracle on Tuesday?
ORCL Oracle Corp
FMP Stock News
Original source text
IBM reported preliminary second-quarter revenue of $17.2 billion, up 1% year-over-year, but below the $17.86 billion consensus estimate, with CEO Arvind Krishna calling the results "disappointing" in a letter to investors. Adjusted EPS came in at $2.93, versus the $3.02 estimate, while GAAP EPS was down 2% year-over-year.

• Oracle stock is testing lower boundaries. Why did ORCL hit a new low?

New AI-Native BuilderIn a separate release today, Oracle rolled out an AI-native builder experience for "Fusion Agentic Applications," adding a unified workflow that spans no-code, low-code and pro-code development inside Oracle Fusion Applications.

The update also introduces an AI Studio Skill that lets developers use tools like VS Code, OpenAI Codex, Claude Code, CLIs, and Git while keeping Fusion-native governance, security and auditability.

Expands OPERA Cloud With Loews Hotels IntegrationOracle also disclosed it is expanding its OPERA Cloud services to enhance operations for Loews Hotels.

Loews Hotels is integrating Oracle’s OPERA Cloud Central services to improve guest recognition and distribution across its U.S. properties. This unified platform aims to optimize operations and enhance guest experiences, showcasing Oracle’s ongoing commitment to providing integrated solutions in the hospitality sector.

ORCL Technical Analysis: Oversold Signals and Key Moving AveragesCurrently, Oracle is trading at $130.60, significantly below its moving averages, with the 20-day simple moving average (SMA) at $154.78, indicating it is 16.9% below this level. The stock has experienced a notable decline of 43.57% over the past year, reflecting ongoing bearish sentiment.

The Relative Strength Index (RSI) currently sits at 26.63, indicating that the stock is in oversold territory, suggesting potential for a rebound if buying interest returns. This momentum indicator measures the speed and change of price movements, and a low RSI indicates that the stock may be undervalued in the short term.

Oracle Vs. Technology Sector: Relative Performance and Recent TrendsOracle’s performance is lagging behind the Technology sector, which is currently ranked six out of 11 sectors. The sector has gained 0.15% today, but Oracle’s decline of almost 1% suggests it is facing company-specific challenges despite a generally stable environment for tech stocks.

Over the past 30 days, the Technology sector has seen a decline of 5.27%, contrasting with a strong 90-day performance of 20.88%. This indicates that while the sector has had a positive longer-term trend, recent pressures are affecting individual stocks such as Oracle.

Oracle Earnings Preview and Analyst Price TargetsLooking further out, the next major catalyst for the stock arrives with the Sept. 8 (estimated) earnings report. Analysts expect earnings per share of $1.67, up from $1.47 in the same quarter last year, and revenue of $19.12 billion, up from $14.93 billion.

EPS Estimate: $1.67 (Up from $1.47) Revenue Estimate: $19.12 billion (Up from $14.93 billion) Valuation: P/E of 22.6x (Indicates fair valuation) Analyst Consensus & Recent Actions: The stock carries a Buy rating with a consensus price target of $268.79. Recent analyst moves include:

Bernstein: Outperform (Raises target to $325 on June 11) RBC Capital: Sector Perform (Maintains target to $190 on June 11) TD Cowen: Buy (Maintains target to $300 on June 11) How Oracle Ranks On Value, Growth and MomentumBelow is the Benzinga Edge scorecard for Oracle, highlighting its strengths and weaknesses compared to the broader market:

Value: Weak (Score: 21.62) — Trading at a steep premium relative to peers. Growth: Strong (Score: 91.45) — Indicates robust growth potential relative to the market. Momentum: Weak (Score: 5.43) — Stock is underperforming the broader market. The Verdict: Oracle’s Benzinga Edge signal reveals a mixed profile, with strong growth potential but weak momentum and value indicators. This suggests that while the company may have future growth opportunities, current market conditions are challenging its performance.

Top ETFs Holding Oracle Stock (ORCL)Significance: Because Oracle carries such a heavy weight in these funds, any significant inflows or outflows for these ETFs will likely trigger automatic buying or selling of the stock.

ORCL Stock Price Today: Shares Trade Lower TuesdayORCL Stock Price Activity: Oracle shares were down 1.81% at $129.43 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo via Shutterstock 

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-14 16:19 27d ago
2026-07-14 10:30 27d ago
Wells Fargo (WFC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
WFC Wells Fargo
FMP Stock News
Original source text
For the quarter ended June 2026, Wells Fargo (WFC - Free Report) reported revenue of $22.62 billion, up 8.6% over the same period last year. EPS came in at $1.96, compared to $1.54 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $21.8 billion, representing a surprise of +3.76%. The company delivered an EPS surprise of +13.3%, with the consensus EPS estimate being $1.73.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Wells Fargo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Average Balance - Total interest-earning assets: $2044.61 billion versus the five-analyst average estimate of $2037.35 billion.Book value per common share: $54.48 compared to the $53.96 average estimate based on five analysts.Return on equity (ROE) - Financial Ratios: 15% compared to the 12.8% average estimate based on five analysts.Return on assets (ROA) - Financial Ratios: 1.2% versus the five-analyst average estimate of 1%.Efficiency Ratio: 60% versus 63.2% estimated by five analysts on average.Net loan charge-offs as a % of average total loans (annualized): 0.3% versus 0.4% estimated by five analysts on average.Net interest margin on a taxable-equivalent basis: 2.4% compared to the 2.4% average estimate based on five analysts.Total nonperforming assets: $7.94 billion versus $8.92 billion estimated by four analysts on average.Total nonaccrual loans: $7.64 billion versus $8.62 billion estimated by four analysts on average.Net loan charge-offs: $876 million versus $1.15 billion estimated by four analysts on average.Common Equity Tier 1 (CET1) - Standardized Approach: 10.3% versus 10.1% estimated by three analysts on average.Tier 1 Leverage Ratio: 6.9% versus the three-analyst average estimate of 6.9%.View all Key Company Metrics for Wells Fargo here>>>

Shares of Wells Fargo have returned +5.5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
2026-07-14 16:19 27d ago
2026-07-14 10:32 27d ago
Wells Fargo profit jumps as fee income, credit quality beat estimates
WFC Wells Fargo
FMP Stock News
Original source text
Wells Fargo & Co (NYSE:WFC, XETRA:NWT) reported second-quarter profit that topped Wall Street expectations on Tuesday, as strong fee income and improved credit performance offset pressure on the bank's net interest margin.

The bank posted earnings of $2 per share, well above analysts' estimate of $1.72, on revenue of $22.62 billion, compared with expectations of $21.87 billion. Net income rose to $6.41 billion from $5.49 billion a year earlier.

Net interest income came in at $12.32 billion, in line with estimates, while net loan charge-offs of $876 million came in better than the $1.1 billion analysts had forecast, marking a 10 basis point improvement from a year ago.

Average loans grew 12% year-over-year to $1.03 trillion, while average deposits rose 10% to $1.47 trillion.

"The biggest positive from the quarter was the combination of strong fee income and better credit performance, which drove core PPNR above our estimate and helped offset NIM pressure," analysts at Jefferies noted.

Corporate and investment banking revenue climbed 16% year-over-year to $5.43 billion, while wealth and investment management revenue rose 13% to $3.89 billion. Consumer banking and lending revenue increased 6% to $10.29 billion, and commercial banking revenue also grew 6% to $3.12 billion.

Wells Fargo repurchased 37.4 million shares for $3 billion during the quarter and said it expects to raise its third-quarter common dividend by 11% to $0.50 per share.

The bank reiterated its full-year guidance, projecting net interest income of roughly $50 billion and noninterest expense of about $55.7 billion.

"We view the quarter as positive and expect investors to focus primarily on whether WFC can sustain strong NII growth despite NIM pressure, particularly now that management has reaffirmed its 2026 NII outlook," Jefferies said.
2026-07-14 16:19 27d ago
2026-07-14 10:40 27d ago
These 5 Bank Earnings May Have Just Crushed the Bear Case for the U.S. Economy
WFC Wells Fargo
FMP Stock News
Original source text
The financial sector hasn’t inspired much confidence in 2026. The State Street Financial Select Sector SPDR ETF (NYSEARCA:XLF) has gained only about 3% this year and roughly 8% over the past 12 months, trailing much of the broader market. Investors have viewed that weakness as more than just a stock market story. 

Banks sit at the center of the economy, so when they lag, recession fears tend to grow louder. This year, those concerns were fueled by the Federal Reserve’s seemingly hawkish interest rate stance, renewed regulatory scrutiny of consumer lending, and the growing migration of corporate borrowers toward private credit markets. 

Yet second-quarter earnings from the nation’s biggest banks just challenged nearly every part of that bearish narrative.

The Numbers Paint a Very Different Economic Picture If the U.S. economy were slipping into recession, it would be difficult to explain the earnings reports delivered by JPMorgan Chase (NYSE:JPM | JPM Price Prediction), Bank of America (NYSE:BAC), Wells Fargo (NYSE:WFC), Goldman Sachs (NYSE:GS), and Citigroup (NYSE:C).

According to each company’s second-quarter earnings release, the group posted results that either exceeded Wall Street expectations or established new company records.

Most notable was JPMorgan Chase, which generated the largest quarterly profit ever reported by a U.S. bank. The bank earned $7.70 per share, well ahead of consensus estimates near $5.72, while net income climbed 41% from a year ago.

Here’s what the major banks told investors:

Bank Key Takeaway JPMorgan Chase Record quarterly profit and strong investment banking activity Bank of America Healthy consumer spending and stable credit quality Wells Fargo Loan performance remained resilient with disciplined expense control Goldman Sachs Investment banking and trading activity accelerated Citigroup Broad-based growth across institutional and consumer businesses Individually, any one of these reports could have reflected company-specific strengths. Together, they tell a broader story about the economy.

Healthy Businesses And Healthy Consumers Still Matter Bank earnings are valuable because they offer one of the widest windows into economic activity. These institutions lend to consumers, finance businesses, underwrite corporate debt, advise on mergers, process credit card transactions, and monitor loan performance across millions of customers.

The latest reports showed strength in several areas that typically weaken before a recession. Investment banking revenue increased as mergers, acquisitions, IPOs, and debt issuance accelerated. That suggests corporate executives remain willing to invest capital rather than retreat.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and JPMorgan Chase didn't make the cut. Grab the names FREE today.

Consumer banking also remained healthy. Credit-loss provisions stayed relatively contained, indicating households continue making loan and credit card payments despite higher interest rates. Stable net interest income across many of the banks also pointed to healthy deposit bases and continued lending activity.

Granted, bank earnings aren’t perfect economic forecasting tools. Trading revenue can fluctuate with market volatility, and banks often benefit from one-time events. But when five of the country’s largest financial institutions all deliver strong results during the same quarter, dismissing the message becomes much harder.

Wall Street is screaming recession, but big bank balance sheets are telling a different story. Discover the massive disconnect between market fear and the record profits defying the bearish narrative. © 24/7 Wall St. Why Investors May Want To Reconsider Financials Ironically, these earnings arrived after months of investors treating financial stocks as recession warnings. The sector’s underperformance reflected legitimate concerns over Fed policy, tighter regulation, and private credit competition. Yet if economic growth remains intact, many of those worries may already be reflected in bank valuations.

Strong earnings also ripple beyond banks. Healthy capital markets benefit asset managers, insurers, exchanges, and payment companies. More importantly, resilient bank profits reinforce confidence that corporate America and consumers continue spending, borrowing, and investing.

That doesn’t eliminate risks. Investors should still watch management commentary for signs of slowing loan growth, rising loan-loss provisions, or weakening consumer credit trends during the second half of the year. Those indicators often shift before headline economic data does.

Key Takeaway In short, the latest earnings season delivered one of the strongest arguments yet against an imminent recession. According to the banks’ earnings releases, corporate dealmaking remains active, consumers continue paying their bills, and credit quality remains stable. Those aren’t the conditions that typically precede a sharp economic downturn.

For investors, the message extends beyond Wells Fargo, Bank of America, or JPMorgan. Financial stocks may deserve another look after a year of lagging performance, while the broader market gains another piece of evidence supporting the soft-landing narrative. Regardless of whether every economic indicator agrees, Wall Street’s largest banks just made a compelling case that the U.S. economy remains far more resilient than many expected.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and JPMorgan Chase didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.
2026-07-14 16:19 27d ago
2026-07-14 11:51 27d ago
June CPI Goes Negative on Low Oil Prices, Banks Report for Q2
WFC Wells Fargo
FMP Stock News
Original source text
Key Takeaways June CPI Reached -0.4%, 3.5% Inflation RateLow Oil Prices from June's MOU Brought CPI LowerTensions Heat Up in Strait of Hormuz CurrentlyQ2 Results Good for JPM, C, BAC & More Tuesday, July 14th, 2026

We have lots of big stock market news ahead of today’s opening bell: Q2 earnings season shifts to a new gear with several of the top banks on Wall Street reporting, aggressions continue to boil in the Strait of Hormuz after more U.S. bombs strike Iran’s interior, and June inflation data takes a downward route for the third-straight month.

June CPI: 1st Negative Print Since Covid Era
For the first time since May 2020 — when the Covid pandemic was busy hitting the U.S. economy for a third-straight month — the Consumer Price Index (CPI) for June came in negative: -0.4%. This is a deeper cut than the -0.2% analysts had been expecting and a big drop from the +0.5% reported for May. It’s the lowest figure since April 2020’s -0.8%.

The Memorandum of Understanding (MOU) between the U.S. and Iran was signed on the 17th of June, and with that the Strait of Hormuz was again able to see oil tanker traffic pass in and out of the Persian Gulf. Global prices of crude oil dropped -21% as a result, as the Mideast oil trade normalized, which led to a -5.7% drop in monthly oil prices in this morning’s CPI report.

Subtracting volatile food and energy costs, core CPI month over month was flat in June — better than the +0.2% consensus, which had matched May’s unrevised tally. This equals January 2021,  just ahead of the Great Reopening, which saw prices soar once the pandemic began to abate. (We also had no CPI data for October or November of 2025, due to the lengthy federal government shutdown.)

Year over year, not only does headline CPI (aka “the Inflation Rate”) thankfully sink back below 4% after May’s +4.2% — which was the highest in three years — but it goes back near March lows: +3.5%. This is -30 basis points (bps) below estimates. Core CPI year over year also dipped -30 bps from the +2.9% expected and reported for May, matching March’s level.

These numbers could not be reasonably expected to have performed better in our current economic climate. That said, these are necessarily backward-looking figures, and now that the Strait of Hormuz appears ready to close again, it’s unlikely these complimentary June CPI results will hold at these levels in the near term.

Q2 Earnings Parade Begins in Earnest: JPM, C, BAC, WFC, GS
One early non-tech beneficiary of the heady AI trade over the past year has been the big banks, as we see from this morning’s Q2 earnings results. Leading firm JPMorgan Chase (JPM - Free Report) posted a +9.8% earnings beat this morning, with earnings per share of $6.14 on $57.35 billion in quarterly revenues, up +16.7% from expectations. For more on JPM’s earnings, click here.

Citigroup (C - Free Report) performed even better on its bottom line: earnings of $3.15 per share outpaced the Zacks consensus by +15.8%, while revenues of $24.77 billion topped expectations by +4.59% for Q2. Pre-market shares are selling -2% on the news, but had gained more than +20% year to date. For more on C’s earnings, click here.

Zacks Rank #3 (Hold)-rated Bank of America (BAC - Free Report) posted earnings of $1.21 per share versus $1.13 projected, and +34% year over year. Revenues also outperformed expectations, but by less-gaudy numbers than JPMorgan or Citi: $31.56 billion versus $30.62 billion estimated. The Charlotte-based bank has only missed earnings estimates once in the past five years.

Wells Fargo (WFC - Free Report) shares had initially gone up on the Q2 report, but are soft ahead of the open. Earnings of $1.96 per share beat estimates by +13.3%, while revenues of $22.62 billion was +3.76% ahead of forecasts. Net interest margins were squeezed in the quarter, however, leading investors to put a check on the stock for now. For more on WFC’s earnings, click here.

Top investment bank Goldman Sachs (GS - Free Report) crushed earnings estimates in its Q2 results ahead of the open, with earnings of $20.98 per share nearly doubling year over year, and zooming past the $14.47 billion in the Zacks consensus. Revenues of $20.34 billion posted an eye-opening +23.3% beat over estimates. For more of GS’ earnings, click here.

Questions or comments about this article and/or author? Click here>>
2026-07-14 16:19 27d ago
2026-07-14 12:04 27d ago
Wells Fargo & Company Q2 Earnings Call Highlights
WFC Wells Fargo
FMP Stock News
Original source text
Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and MastercardWells Fargo & Company NYSE: WFC reported stronger second-quarter 2026 results, with executives pointing to broad-based revenue growth, disciplined expenses, improved credit performance and balance sheet growth following the removal of the company’s asset cap last year.

Chief Executive Officer Charlie Scharf said diluted earnings per share rose 25% from a year earlier to $2, while revenue increased 9%. Net interest income grew 5%, and non-interest income rose 13%, reflecting what Scharf described as progress toward building a more balanced revenue mix with higher fee-based revenue.

Get Wells Fargo & Company alerts:

3 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress Test“We are clearly benefiting from the economic strength we see in the U.S., but the investments we are making and our improved operating discipline drove strong momentum and continued to result in improved performance,” Scharf said.

Chief Financial Officer Mike Santomassimo said net income increased 17% year over year to $6.4 billion. The quarter included $132 million, or $0.04 per share, of discrete tax benefits tied to the resolution of prior-period matters.

Revenue Growth Across All Operating Segments Ally Financial Is Back to Basics—And Investors Are WatchingScharf said each of Wells Fargo’s operating segments generated higher net interest income and non-interest income compared with a year earlier. In Consumer Banking and Lending, revenue rose 6%, helped by growth in checking accounts, credit cards and auto lending. Scharf said consumer primary checking accounts have increased year over year for 13 consecutive quarters, supported by investments in marketing and digital account opening.

Credit card momentum continued, with new accounts increasing 46% from a year earlier. Scharf said the company has enhanced its credit card products over the past five years and improved customer experience, but noted that rapid growth in the business carries near-term profitability pressure because of upfront costs tied to marketing, promotional rates, onboarding and reserves. He said card vintages from 2022 through 2024 are now adding to profitability, while larger 2025 and 2026 vintages are still absorbing upfront costs.

Auto lending also expanded, with originations rising 41% year over year and average balances up 31%. Scharf said growth was partly due to Wells Fargo becoming the preferred financing provider for Volkswagen and Audi vehicles in the U.S., adding that credit performance has remained in line with expectations.

In Wealth and Investment Management, revenue increased 13%. Client assets rose 15% to more than $2.4 trillion, driven by higher market valuations and four consecutive quarters of positive net flows. Scharf said Wells Fargo has invested more than $1 billion in recent years to modernize the unit’s technology platform, including the second-quarter launch of Advisor Gateway, a desktop platform with generative AI capabilities.

Investment Banking and Markets Drive CIB Results Corporate and Investment Banking revenue rose 16% from a year earlier. Scharf said markets revenue grew 24%, aided by balance sheet growth to support client financing activity. He noted that while this activity can lower net interest margin because it carries lower spreads, it has “good returns and profitability” and can support broader client relationships.

Santomassimo said Wells Fargo has increased its markets balance sheet by $198 billion since the end of 2024, with about 60% in financing balances, 20% in trading and 20% in lending within the business. He said the company is tracking client-level results and is seeing additional business from clients receiving incremental financing.

Banking revenue within Corporate and Investment Banking rose 20%, supported by investment banking fees and activity in equity and debt capital markets. Santomassimo said firmwide investment banking fees exceeded $900 million in the quarter, a record. Scharf highlighted Wells Fargo’s year-to-date leveraged finance market share of 7.2%, its No. 3 ranking in that category, a 3.8% share in equity capital markets and a move from No. 9 to No. 4 among U.S. advisors by announced M&A deal volume.

Commercial Banking revenue increased 6% from a year earlier. Scharf said targeted hiring in 20 high-density markets where Wells Fargo is under-penetrated has helped drive client growth and higher loan and deposit balances. He also said the company is investing in treasury management and payments, including blockchain-based payment rails intended to make cross-border payments faster, more transparent and more predictable.

Expenses, Headcount and Capital Returns Expenses increased 2% from a year earlier, reflecting investments in technology, advertising and revenue-related compensation, partially offset by efficiency initiatives. Santomassimo said Wells Fargo’s efficiency ratio improved to 60%, down four percentage points from a year earlier.

Scharf said headcount has declined for 24 consecutive quarters. The company ended the second quarter with 197,000 employees, down 79,000 from six years ago, 15,000 from last year and 3,500 from the prior quarter. He said Wells Fargo is using those efficiencies to fund investments including branch bankers, investment advisors, commercial banking relationship managers, investment bankers, traders, marketing, product development, AI and cybersecurity.

Wells Fargo returned more than $9.8 billion of capital to shareholders in the first half of 2026, including $7 billion of common stock repurchases. Santomassimo said the company repurchased $3 billion of common stock in the second quarter, and common shares outstanding declined 6% from a year earlier. The company’s common equity Tier 1 ratio was 10.3%, within its 10% to 10.5% target range and above its regulatory minimum plus buffers of 8.5%.

Scharf said Wells Fargo expects to raise its third-quarter common stock dividend by 11% to $0.50 per share, subject to board approval later this month.

Credit Quality Remains Strong Executives said credit performance remained strong across consumer and commercial portfolios. Santomassimo said the net loan charge-off ratio declined 10 basis points from a year earlier to 34 basis points of average loans. Commercial net loan charge-offs declined to 10 basis points, while consumer loan charge-offs also improved, including continued net recoveries in residential mortgage.

During the question-and-answer session, Santomassimo said consumer delinquency trends have been better than the company modeled throughout the year, with no meaningful deterioration by FICO score or income cohort. He also said Wells Fargo is not seeing systemic issues in the commercial portfolio, though individual borrower issues can arise.

Asked about underwriting conditions, Scharf said consumer lending competition appears broadly consistent, but he described wholesale lending as more varied. He said significant capital is being deployed by banks and non-banks across risk assets, including areas related to data centers and strategic transactions. Scharf said Wells Fargo is staying within its risk tolerances and underwriting only the parts of transactions where it is comfortable with the credit profile.

Outlook Maintained as NIM Remains in Focus Santomassimo said Wells Fargo is maintaining its full-year 2026 net interest income outlook of approximately $50 billion, including about $48 billion excluding markets and about $2 billion from markets. He said average loans rose 12% year over year in the second quarter, and loan growth in the fourth quarter is likely to exceed the mid-single-digit increase the company assumed in January.

Net interest margin declined four basis points from the first quarter, which Santomassimo attributed mainly to growth in interest-bearing deposits and continued growth in markets activity. He said Wells Fargo expects modest net interest margin compression in the third quarter, broadly in line with the second-quarter decline, before stabilization in the fourth quarter.

In response to analyst questions, Scharf emphasized that the pressure on net interest margin is tied to deliberate growth decisions, particularly in markets financing and interest-bearing deposit growth, rather than factors simply “happening” to the company. He said Wells Fargo can slow or reverse some activity if it does not generate the expected returns, but added that early results show higher trading revenue and share gains from clients receiving financing.

Wells Fargo also maintained its 2026 non-interest expense outlook of approximately $55.7 billion. Santomassimo said first-half expenses were in line with expectations, and higher revenue-related expenses in the second half are expected to be offset by efficiency initiatives elsewhere.

Scharf reiterated confidence in Wells Fargo’s medium-term target of a sustainable return on tangible common equity of 17% to 18%. The company reported ROTCE of 17.7% in the second quarter and 16.1% for the first half of 2026. Scharf said venture capital equity gains helped returns in the quarter, but he said broader growth and efficiency trends are what support confidence in reaching the target over a “reasonable timeframe,” assuming favorable conditions continue.

About Wells Fargo & Company NYSE: WFCWells Fargo & Company is a diversified, U.S.-based financial services company headquartered in San Francisco, California. Founded in 1852 by Henry Wells and William G. Fargo, the firm has evolved from its origins in express delivery and pioneer-era banking into one of the largest full-service banks in the United States. The company provides a broad range of financial products and services to individual, small business, commercial, and institutional clients. Charles W. Scharf serves as chief executive officer.

Wells Fargo operates across several core business segments, including consumer banking and lending, commercial banking, corporate and investment banking, and wealth and investment management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Wells Fargo & Company Right Now?Before you consider Wells Fargo & Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wells Fargo & Company wasn't on the list.

While Wells Fargo & Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
2026-07-14 16:19 27d ago
2026-07-14 12:06 27d ago
CPI fell More Than Expected
WFC Wells Fargo
FMP Stock News
Original source text
We have lots of big stock market news ahead of today’s opening bell: Q2 earnings season shifts to a new gear with several of the top banks on Wall Street reporting, aggressions continue to boil in the Strait of Hormuz after more U.S. bombs strike Iran’s interior, and June inflation data takes a downward route for the third-straight month.

June CPI: 1st Negative Print Since Covid EraFor the first time since May 2020 — when the Covid pandemic was busy hitting the U.S. economy for a third-straight month — the Consumer Price Index (CPI) for June came in negative: -0.4%. This is a deeper cut than the -0.2% analysts had been expecting and a big drop from the +0.5% reported for May. It’s the lowest figure since April 2020’s -0.8%.

The Memorandum of Understanding (MOU) between the U.S. and Iran was signed on the 17th of June, and with that the Strait of Hormuz was again able to see oil tanker traffic pass in and out of the Persian Gulf. Global prices of crude oil dropped -21% as a result, as the Mideast oil trade normalized, which led to a -5.7% drop in monthly oil prices in this morning’s CPI report.

Subtracting volatile food and energy costs, core CPI month over month was flat in June — better than the +0.2% consensus, which had matched May’s unrevised tally. This equals January 2021,  just ahead of the Great Reopening, which saw prices soar once the pandemic began to abate. (We also had no CPI data for October or November of 2025, due to the lengthy federal government shutdown.)

Year over year, not only does headline CPI (aka “the Inflation Rate”) thankfully sink back below 4% after May’s +4.2% — which was the highest in three years — but it goes back near March lows: +3.5%. This is -30 basis points (bps) below estimates. Core CPI year over year also dipped -30 bps from the +2.9% expected and reported for May, matching March’s level.

These numbers could not be reasonably expected to have performed better in our current economic climate. That said, these are necessarily backward-looking figures, and now that the Strait of Hormuz appears ready to close again, it’s unlikely these complimentary June CPI results will hold at these levels in the near term.

Q2 Earnings Parade Begins in Earnest: JPM, C, BAC, WFC, GSOne early non-tech beneficiary of the heady AI trade over the past year has been the big banks, as we see from this morning’s Q2 earnings results. Leading firm JPMorgan Chase (JPM - Free Report) posted a +9.8% earnings beat this morning, with earnings per share of $6.14 on $57.35 billion in quarterly revenues, up +16.7% from expectations.

Citigroup (C - Free Report) performed even better on its bottom line: earnings of $3.15 per share outpaced the Zacks consensus by +15.8%, while revenues of $24.77 billion topped expectations by +4.59% for Q2. Pre-market shares are selling -2% on the news, but had gained more than +20% year to date.

Zacks Rank #3 (Hold)-rated Bank of America (BAC - Free Report) posted earnings of $1.21 per share versus $1.13 projected, and +34% year over year. Revenues also outperformed expectations, but by less-gaudy numbers than JPMorgan or Citi: $31.56 billion versus $30.62 billion estimated. The Charlotte-based bank has only missed earnings estimates once in the past five years.

Wells Fargo (WFC - Free Report) shares had initially gone up on the Q2 report, but are soft ahead of the open. Earnings of $1.96 per share beat estimates by +13.3%, while revenues of $22.62 billion was +3.76% ahead of forecasts. Net interest margins were squeezed in the quarter, however, leading investors to put a check on the stock for now.

Top investment bank Goldman Sachs (GS - Free Report) crushed earnings estimates in its Q2 results ahead of the open, with earnings of $20.98 per share nearly doubling year over year, and zooming past the $14.47 billion in the Zacks consensus. Revenues of $20.34 billion posted an eye-opening +23.3% beat over estimates.
2026-07-14 16:18 27d ago
2026-07-14 11:00 27d ago
Interactive Brokers Builds Out One of the Most Comprehensive and Low-Cost Solutions for Accessing Cryptocurrency Available
APT Alpha Pro Tech
FMP Stock News
Original source text
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the addition of nine new tokens for trading through zerohash and three new tokens through Paxos. The company also introduced the ability to transfer funds to external wallets via stablecoin. Clients can now withdraw USD from their IBKR account via automatic conversion to USDC, PYUSD (PayPal USD), or RLUSD (Ripple USD), extending the stablecoin funding flexibility already available for deposits. Together, these additions strengthen one of the most capable and cost-effective crypto trading experiences available from any multi-asset broker.

"We believe digital assets should be integrated into a client's broader financial experience, not treated separately," said Milan Galik, Chief Executive Officer of Interactive Brokers. "As stablecoins become a more widely used method of payment and transfer, we remain focused on giving clients access to digital assets alongside the broad range of products, asset classes and global markets available through the Interactive Brokers platform.”

While many traditional brokers are just beginning to offer crypto or charge a premium for it, and dedicated crypto exchanges lack multi-asset brokerage capabilities, cryptocurrency trading on the IBKR platform is built around four pillars that set it apart:

Highly competitive costs across multi-asset trading. IBKR charges up to 85% less than competitors to trade crypto with crypto commissions starting at just 0.12% to 0.18% of trade value with a USD 1.75 minimum per order and no added spreads, markups, or custody fees. Recently launched crypto offerings from traditional brokers charge as much as 0.75%, and even the most competitive alternatives are still two to four times more expensive, with some platforms charging up to 1.20% or more.

Stablecoin funding that most traditional brokers do not offer. In addition to traditional means such as ACH and wire, Interactive Brokers now offers bidirectional funding via stablecoin. Clients can fund their accounts and transfer to external destinations like personal cryptocurrency wallets, using three stablecoins – USDC issued by Circle, the Ripple stablecoin (RLUSD), and the PayPal stablecoin (PYUSD). Funding and external transfers are processed near-instantly, 24/7, including on weekends and holidays. This allows clients to move capital onto the platform and begin trading across 170 global markets within minutes, any day of the year.

Full crypto transfer flexibility. Eligible clients can send and receive supported digital assets to and from both custodial and non-custodial wallets.

A unified multi-asset platform. Clients can trade cryptocurrency alongside a broad range of financial assets including stocks, options, futures, bonds, funds and prediction markets. There are no separate apps and no need to switch between platforms.

New Token Additions

Today's expansion adds nine tokens through zerohash, including Pax Gold (PAXG), a gold-backed digital token representing fully allocated, physical gold held in professional vault facilities.

New Additions via zerohash:

Aave (AAVE)

Aptos (APT)

Canton (CC)

Lido DAO (LDO)

Monad (MON)

NEAR Protocol (NEAR)

Plasma (XPL)

Pax Gold (PAXG)

Uniswap (UNI)

Also Available via Paxos Trust Company, N.A.:

Aave (AAVE)

Uniswap (UNI)

Pax Gold (PAXG)

Already Available via zerohash: Avalanche (AVAX), Bitcoin (BTC), Bitcoin Cash (BCH), Cardano (ADA), Chainlink (LINK), Dogecoin (DOGE), Ethereum (ETH), Litecoin (LTC), Ripple (XRP), Solana (SOL), and Sui (SUI).

Already Available via Paxos: Bitcoin (BTC), Bitcoin Cash (BCH), Chainlink (LINK), Ethereum (ETH), Litecoin (LTC), Polygon (MATIC), and Solana (SOL)

For additional information, please visit:

US and countries served by IBLLC: [url="]Cryptocurrency Trading [/url]
United Kingdom: Cryptocurrency Trading

Availability of products varies by Interactive Brokers affiliate and client country of residence. Trading in digital assets, including cryptocurrencies, is especially risky and is only for individuals with a high risk tolerance and the financial ability to sustain losses.

Bidirectional funding via Stablecoin is not available to clients of Interactive Brokers (U.K.) Limited or Interactive Brokers Ireland Limited. The new crypto-assets are not available to clients of Interactive Brokers Ireland Limited.

The best-informed investors choose Interactive Brokers.

About Interactive Brokers Group, Inc.:

Interactive Brokers Group, Inc. (NASDAQ: IBKR) is a member of the S&P 500. Its affiliates provide automated trade execution and custody of securities, commodities, foreign exchange, and prediction markets around the clock on over 170 markets in numerous countries and currencies from a single unified platform to clients worldwide. We serve individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation have enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Interactive Brokers has consistently earned recognition as a top broker, garnering multiple awards and accolades from respected industry sources such as Barron's, Investopedia, Stockbrokers.com, and many others.

Follow Interactive Brokers on social media: Facebook, Instagram, LinkedIn, Reddit, X (Twitter),TikTok, YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20260714178768/en/
2026-07-14 16:17 27d ago
2026-07-14 10:09 27d ago
Lost Money on First Solar, Inc. (FSLR)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
FSLR First Solar
FMP Stock News
Original source text
, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of First Solar, Inc. (NASDAQ: FSLR).

Shareholders who purchased shares of FSLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/first-solar-inc-loss-submission-form-3/?id=193596&from=4

CLASS PERIOD: February 26, 2025 to February 24, 2026

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) defendants had overstated First Solar's capacity to manage the impact of U.S. tariff policy on the Company's business; (ii) defendants understated the extent to which its responses to U.S. tariff policy, including the intentional underutilization of production facilities in Malaysia and Vietnam, and attempted relocation of production to the U.S., were likely to negatively impact First Solar's projected performance in the 2026 fiscal year; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.

DEADLINE: August 24, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/first-solar-inc-loss-submission-form-3/?id=193596&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of FSLR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 24, 2026. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm
2026-07-14 16:17 27d ago
2026-07-14 10:17 27d ago
FSLR Shareholder Alert: August 24, 2026 Lead Plaintiff Deadline in First Solar, Inc. Securities Class Action - Contact SueWallSt
FSLR First Solar
FMP Stock News
Original source text
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in First Solar, Inc. (NASDAQ: FSLR) during the period from February 26, 2025 through February 24, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

FSLR shares suffered two corrective declines during the Class Period, falling $27.67 per share (10.29%) on January 7, 2026 and an additional $33.09 per share (13.61%) on February 25, 2026, closing at $210.12. The Court has set August 24, 2026 as the deadline to apply for lead plaintiff appointment.

Notice to Institutional Holders

Pension funds, mutual funds, endowments, and asset managers that acquired FSLR securities during the Class Period face potential fiduciary obligations to evaluate recovery options on behalf of beneficiaries. The lawsuit contends that First Solar and its senior executives made materially false and misleading statements about the Company's capacity to manage U.S. tariff policy impacts, while understating how production curtailments at international facilities and costly onshoring efforts would harm projected 2026 performance.

With over 107 million shares of Class A common stock outstanding as of April 24, 2026, institutional holders likely represent a substantial portion of affected purchasers.

ERISA and Fiduciary Considerations

Fiduciaries of plans that held FSLR securities during the Class Period should consider whether plan assets were acquired at prices allegedly inflated by undisclosed risks.

Fiduciaries have a duty to act prudently and in the best interest of plan participants when evaluating potential recovery claimsInstitutional investors with the largest documented losses are best positioned to seek lead plaintiff appointment and direct case strategyLead plaintiff appointment carries no additional financial obligation; securities class actions are handled on a contingency basisInstitutions serving as lead plaintiff gain direct oversight of settlement negotiations and litigation strategyFailure to evaluate recovery options in cases involving significant portfolio losses may itself raise fiduciary questionsThe PSLRA favors institutional lead plaintiffs with substantial stakes in the outcome Portfolio Impact Assessment

The complaint alleges that throughout the Class Period, the Company reassured investors that the U.S. trade environment was "long term favorable" and that production curtailments at Malaysian and Vietnamese facilities were temporary, strategic measures. As alleged, these statements concealed the severity of demand deterioration, the 6.6 gigawatt booking termination by BP affiliates, and the $330 million cost burden of onshoring production to a new South Carolina facility. When these realities surfaced, portfolio valuations declined sharply.

Case Summary

The securities action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint charges that corrective information emerged in two phases: a January 2026 Jefferies downgrade citing continued international facility "pain points" and underutilization concerns, followed by the Company's February 2026 earnings announcement revealing missed expectations and below-consensus 2026 revenue guidance.

"Institutional investors play a critical role in securities class actions. Their participation ensures vigorous representation of the entire class and can meaningfully influence the trajectory of litigation and recovery." -- Joseph E. Levi, Esq.

Contact us to learn more about institutional recovery options or contact Joseph E. Levi, Esq. at (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the FSLR Lawsuit

Q: Who is eligible to join the FSLR investor lawsuit? A: Investors who purchased FSLR stock or securities between February 26, 2025 and February 24, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did FSLR stock drop? A: Shares suffered two significant declines during the Class Period. On January 7, 2026, shares fell $27.67 (10.29%) after Jefferies downgraded the stock, citing international facility underutilization concerns. On February 25, 2026, shares fell an additional $33.09 (13.61%) to close at $210.12 after the Company reported disappointing results and issued lower-than-expected 2026 revenue guidance.

Q: What is the FSLR lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is August 24, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What do FSLR investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Contact SueWallSt, a brand of Levi & Korsinsky LLP, for a no-cost, no-obligation case evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I already sold my FSLR shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: Can I join a different law firm's lawsuit instead? A: Multiple firms often file competing complaints. The court consolidates and appoints a single lead counsel. Contacting Levi & Korsinsky before August 24, 2026 ensures your losses are considered.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.        
2026-07-14 16:17 27d ago
2026-07-14 12:00 27d ago
Bronstein, Gewirtz & Grossman LLC Urges First Solar, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
FSLR First Solar
FMP Stock News
Original source text
New York, New York--(Newsfile Corp. - July 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against First Solar, Inc. (NASDAQ: FSLR) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired First Solar securities between February 26, 2025 and February 24, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/FSLR.

First Solar Case Details

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that:

Defendants had overstated First Solar's capacity to manage the impact of U.S. tariff policy on the Company's business Defendants understated the extent to which its responses to U.S. tariff policy, including the intentional underutilization of production facilities in Malaysia and Vietnam, and attempted relocation of production to the U.S., were likely to negatively impact First Solar's projected performance in the 2026 fiscal year; as a result, Defendants' public statements were materially false and misleading at all relevant times.What's Next for First Solar Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/FSLR, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in First Solar you have until August 24, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to First Solar Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for First Solar Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising.
Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302696

Source: Bronstein, Gewirtz & Grossman, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us
2026-07-14 16:17 27d ago
2026-07-14 11:01 27d ago
Realty Income Boosts Liquidity: What Does This Mean for Growth?
O Realty Income
FMP Stock News
Original source text
Key Takeaways Realty Income increased commercial paper capacity to $5.5B from $3B across the U.S. and Europe.O expanded revolving credit facilities to $5.5B, with an accordion feature up to $6.5B.Realty Income's facilities lower drawn borrowing costs by 5 basis points. Realty Income Corporation (O - Free Report) has strengthened its liquidity position, expanding its unsecured multicurrency revolving credit facilities to $5.5 billion from $4 billion, effective July 13, 2026. The REIT also raised its global unsecured commercial paper capacity to $5.5 billion from $3 billion, increasing flexibility for future investments.

The revolving facilities include an accordion option that could lift total borrowing capacity to $6.5 billion, subject to lender commitments. Designed to support growth initiatives in the United States, United Kingdom and continental Europe, the expanded platform gives Realty Income greater capacity to pursue opportunities across multiple property markets and currencies.

Financing terms also improved, with borrowing costs reduced to SOFR plus 80 basis points, five basis points below the previous facilities. Support from a 26-lender syndicate signals institutional confidence in Realty Income’s balance sheet, capital access and investment-grade A3/A- credit ratings amid a selective transaction environment.

The enhanced liquidity supports Realty Income's expansion beyond traditional retail and industrial assets as it broadens its investment strategy. Earlier this month, it formed a programmatic joint venture with Cloud Capital and a global institutional investor targeting hyperscale data centers, a sector benefiting from accelerating demand for artificial intelligence and cloud infrastructure.

The venture’s initial portfolio exceeds $6 billion, with Realty Income committing up to $1.4 billion for a 45% stake in three Northern Virginia hyperscale data centers. By applying its long-term triple-net lease expertise to digital infrastructure, the company is creating another growth channel while diversifying its portfolio and preserving predictable cash flows.

How Are Realty Income's Peers' Balance Sheets Support Growth Plans?Macerich (MAC - Free Report) enhanced its funding flexibility in June 2026, through a forward equity offering of 14 million shares at $23.90 each, with an option for 2.1 million more. The structure allows MAC to lock in pricing while delaying issuance, supporting acquisitions and preserving MAC’s borrowing headroom.

Simon Property Group (SPG - Free Report) issued a €500 million offering of 3.650% unsecured notes due 2031 through its Dutch subsidiary, Simon Global Development B.V. in June 2026. The notes are fully guaranteed by Simon. Proceeds will support general corporate purposes, strengthening the retail REIT’s financial flexibility and overall liquidity.

Realty Income’s Price Performance, Valuation and EstimatesShares of Realty Income have risen 3.3% over the past month, outperforming the broader industry and the S&P 500 Index.

Image Source: Zacks Investment Research

In terms of forward 12-month Price/Earnings (P/E), Realty Income is currently trading at 14.16X, which is at a discount to the industry average of 16.92X.

Image Source: Zacks Investment Research

Realty Income’s estimate revisions reflect a positive trend. The Zacks Consensus Estimate for fiscal 2026 EPS has been revised marginally upward over the past month. The consensus estimate calls for 4% growth year over year.

Image Source: Zacks Investment Research

Currently, Realty Income carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-07-14 16:17 27d ago
2026-07-14 11:41 27d ago
Meet Wall Street's Safest High-Yield Dividend Stocks
O Realty Income
FMP Stock News
Original source text
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Ilyas nasrulloh / Shutterstock.com

Chasing yield without checking the fine print is how income investors get burned. The safest high-yield dividend stocks share four traits: a long, uninterrupted growth streak, cash flow that comfortably covers the payout, a balance sheet that can absorb a bad cycle, and a business model built on recurring revenue (fee-based pipelines, net leases, or defensive staples). Yield alone is a trap. Yield plus coverage plus consistency is a portfolio.

Using those filters, three names on the NYSE stand out right now. Each pays a high-single-digit or mid-single-digit yield, each has raised the payout for decades, and each generates enough operating cash flow to keep writing checks even when earnings hit an air pocket. Here is the countdown.

3. Universal Corporation Universal Corporation (NYSE:UVV) is the world’s largest leaf-tobacco merchant, and its dividend record is elite: 56 consecutive years of dividend increases, with the quarterly payout just bumped to $0.83 per share. The yield sits at 6.50%.

Safety here is real, but not fortress-grade. Fiscal 2026 was ugly: full-year EPS of $2.64 against a $4.17 consensus, plus a $41.06 million goodwill impairment at the Shank’s ingredients unit and $52.00 million in inventory write-downs on dark air-cured tobacco. Yet operating cash flow of $129.1 million still covered the $81.3 million dividend at 1.59x, and the company refinanced its revolver in December 2025 with roughly $595 million available and maturity extended to December 2030. CEO Preston D. Wigner reiterated the company is “continuing our track record of returning capital to our shareholders.” The dividend is safe. Growth is on hold until tobacco oversupply clears.

2. Enterprise Products Partners Enterprise Products Partners (NYSE:EPD | EPD Price Prediction) is the model of a fee-based midstream MLP. Q4 2025 marked the 27th consecutive year of distribution growth, and the yield today is 5.91%. If you want a monthly income primer, our 7 Monthly Dividend Stocks report is a useful companion read on paycheck-style portfolios.

July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.

Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.

With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.

Q1 2026 set 12 operational records, and adjusted EBITDA rose 10% year over year to $2.69 billion. Distributable cash flow hit $2.7 billion, funding the payout, $116 million of buybacks, and $1.5 billion of retained cash. Full-year 2025 operating cash flow was $8.585 billion against a $4.678 billion dividend payout, a coverage profile most REITs would envy. Trading at a 14 P/E with a forward multiple near 13x, EPD offers yield, growth capex, and a beta of just 0.469. The stock is up 28.27% over the past year.

1. Realty Income Realty Income (NYSE:O) earns the top spot on pure consistency. The net-lease REIT known as “The Monthly Dividend Company” has now paid 670 consecutive monthly dividends and delivered its 114th consecutive quarterly increase. The current yield is 5.07%, with the monthly payout at $0.271.

Q1 2026 AFFO rose 6.6% year over year to $1.13 per share, portfolio occupancy stayed at 98.9%, and rent recapture hit 103.4%. Management raised 2026 investment guidance to $9.5 billion from $8.0 billion, and boosted AFFO guidance to $4.41 to $4.44. Net Debt to Annualized Pro Forma Adjusted EBITDAre improved to 5.2x from 5.4x. CEO Sumit Roy called out “the strength and resiliency of our global investment and operating platforms.” With a beta of 0.729, institutional ownership at 80.345%, and shares up 18.46% over the past year, Realty Income combines the highest payment frequency, the longest unbroken monthly record, and the most diversified property base of the group. That is the definition of safe high yield.

The Bottom Line The premise was simple: high yield only counts when the payout is durable. UVV clears the coverage bar despite an operational hangover, EPD backs its 27-year growth streak with fee-based cash flow that dwarfs the distribution, and Realty Income sits at the top with a monthly cadence, aristocrat status, and an underwriting engine that keeps compounding. For income investors who want yield without white-knuckling every earnings report, this is the shortlist to build around.

Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.

Over 50,000 people already have, along with global giants like General Motors and POSCO.

Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.

Contact [email protected] for any questions or corrections.
2026-07-14 16:16 27d ago
2026-07-14 10:30 27d ago
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
ABBV AbbVie
FMP Stock News
Original source text
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about AbbVie (ABBV - Free Report) .

AbbVie currently has an average brokerage recommendation (ABR) of 1.61, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 32 brokerage firms. An ABR of 1.61 approximates between Strong Buy and Buy.

Of the 32 recommendations that derive the current ABR, 21 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 65.6% and 6.3% of all recommendations.

Brokerage Recommendation Trends for ABBV

Check price target & stock forecast for AbbVie here>>>

The ABR suggests buying AbbVie, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Is ABBV Worth Investing In?Looking at the earnings estimate revisions for AbbVie, the Zacks Consensus Estimate for the current year has declined 0.6% over the past month to $14.23.

Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for AbbVie. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, it could be wise to take the Buy-equivalent ABR for AbbVie with a grain of salt.
2026-07-14 16:16 27d ago
2026-07-14 11:31 27d ago
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns
STNE StoneCo
FMP Stock News
Original source text
Key Takeaways Five stocks met value screens that used low P/B, P/S, P/E and PEG metrics below industry medians.Harmony Biosciences has a projected 3-5-year EPS growth rate of 32.6% and a Value Score of A.Nexa Resources has a projected 3-5-year EPS growth rate of 34.0% and a Value Score of A. Value investors widely favor the price-to-book (P/B) ratio for identifying low-priced stocks with exceptional returns. The ratio is used to compare a stock’s market value/price to its book value.

The P/B ratio is calculated as below:

P/B ratio = market price per share/book value of equity per share

P/B ratio reflects how many times book value investors are ready to pay for a share. So, if the share price is $10 and the book value of equity is $5, investors are ready to pay two times the book value. Ideally, a P/B value under 1.0 is considered good as it indicates that the stock is potentially undervalued. However, value investors often consider stocks with a P/B value under 3.0.

This metric can help identify attractively priced stocks with upside potential. Some such stocks are Harmony Biosciences Holdings (HRMY - Free Report) , StoneCo (STNE - Free Report) , General Motors (GM - Free Report) , Hewlett Packard Enterprise (HPE - Free Report) and Nexa Resources (NEXA - Free Report) . Let us understand the concept of book value.

What is Book Value?There are several ways in which book value can be defined. Book value is the total value that would be left over, according to the company’s balance sheet, if it went bankrupt immediately. In other words, this is what shareholders would theoretically receive if a company liquidates all its assets after paying off all its liabilities.

It is calculated by subtracting total liabilities from the total assets of a company. In most cases, this equates to common stockholders’ equity on the balance sheet. However, depending on the company’s balance sheet, intangible assets should also be subtracted from total assets to determine book value.

Book Value Per Share = (Total Assets – Total Liabilities) ÷ Number of Outstanding Shares

Understanding P/B RatioBy comparing the book value of equity to its market price, we get an idea of whether a company is under- or overpriced. Like P/E or P/S ratios, it is always better to compare the P/B ratio within industries.

A P/B ratio of less than one means that the stock is trading at less than its book value or the stock is undervalued and, therefore, a good buy. Conversely, a stock with a ratio greater than one can be interpreted as being overvalued or relatively expensive.

For example, a stock with a P/B ratio of 2 means that we pay $2 for every $1 of book value. Thus, the higher the P/B, the more expensive the stock.

But there is a warning. A P/B ratio of less than one can also mean that the company is earning weak or even negative returns on its assets or that the assets are overstated. In such a case, the stock should be shunned because it may be destroying shareholder value. Conversely, the stock’s price may be significantly high — thereby pushing the P/B ratio to more than one — in the likely case that it has become a takeover target, a good enough reason to own the stock.

Moreover, the P/B ratio is not without limitations. It is useful for businesses like finance, investments, insurance and banking or manufacturing companies with many liquid/tangible assets on the books. However, it can be misleading for firms with significant R&D expenditure, high debt, service companies, or those with negative earnings.

In any case, the ratio is not particularly relevant as a standalone number. One should analyze other ratios like P/E, P/S and debt to equity before arriving at a reasonable investment decision.

Screening ParametersPrice to Book (common Equity) less than X-Industry Median: A lower P/B compared with the industry average implies that there is enough room for the stock to gain.

Price to Sales less than X-Industry Median: The P/S ratio determines how much the market values every dollar of the company’s sales/revenues — a lower ratio than the industry makes the stock attractive.

Price to Earnings using F(1) estimate less than X-Industry Median: The P/E ratio (F1) values a company based on its current share price relative to its estimated earnings per share — a lower ratio than the industry is considered better.

PEG less than 1: PEG links the P/E ratio to the future growth rate of the company. The PEG ratio portrays a more complete picture than the P/E ratio. A value of less than 1 indicates that the stock is undervalued, and investors need to pay less for a stock that has bright earnings growth prospects.

Current Price greater than or equal to $5: They must all be trading at a minimum of $5 or higher.

Average 20-Day Volume greater than or equal to 100,000: A substantial trading volume ensures that the stock is easily tradable.

Zacks Rank less than or equal to #2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.

Value Score equal to A or B: Our research shows that stocks with a Value Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best opportunities in the value investing space.

5 Low Price-to-Book StocksHere are five of the 13 stocks that qualified for the screening: 

Delaware-based Harmony Biosciences is a neuroscience company developing and commercializing therapies for sleep/wake disorders and rare neurological diseases.

Harmony Biosciences currently has a Value Score of A and a Zacks Rank #1. HRMY has a projected 3-5-year EPS growth rate of 32.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.

StoneCo provides financial technology solutions. The company offers an end-to-end cloud-based technology platform to conduct electronic commerce across in-store, online and mobile channels. StoneCo is based in Sao Paulo, Brazil.

STNE has a Zacks Rank #2 and a Value Score of A. STNE has a projected 3-5-year EPS growth rate of 23.6%.

Detroit, MI-based General Motors is one of the world’s largest automakers. General Motors, along with its strategic partners, produces, sells and services cars, trucks and parts under four core brands — Chevrolet, Buick, GMC and Cadillac. General Motors assembles passenger cars, crossover vehicles, light trucks, sport-utility vehicles, vans and other vehicles.

GM currently has a Zacks Rank #2 and a Value Score of A. The company has a projected 3-5-year EPS growth rate of 15.5%. 

Headquartered in Houston, TX, Hewlett Packard Enterprise is a global enterprise technology company. It provides hardware, software and services that help businesses store, process and manage data across on-premise, cloud and edge environments. The company serves enterprises, governments, telecom operators and financial institutions in more than 150 countries.

Hewlett Packard currently has a Zacks Rank #1 and a Value Score of B. The company has a projected 3-5-year EPS growth rate of 32.0% 

Luxembourg City, Brazil-based Nexa Resources is an integrated zinc producer. It is engaged in developing and operating mining and smelting assets, primarily in Latin America. NEXA currently has a Value Score of A and a Zacks Rank #2. NEXA has a projected 3-5-year EPS growth rate of 34.0%. 
2026-07-14 16:16 27d ago
2026-07-14 10:40 27d ago
Here's Why American International Group (AIG) is a Strong Value Stock
AIG American International Group
FMP Stock News
Original source text
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: American International Group (AIG - Free Report) American International Group is a leading global insurance organization. AIG provides insurance solutions that help businesses and individuals protect their assets and manage risks through AIG operations, licenses and authorizations, as well as network partners. It serves clients in over 200 countries and jurisdictions, ranging from individuals and small and medium-sized businesses to multinational Fortune 500 companies.

AIG is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.99; value investors should take notice.

Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $8.00 per share. AIG also boasts an average earnings surprise of +15.1%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, AIG should be on investors' short list.
2026-07-14 16:15 27d ago
2026-07-14 10:00 27d ago
Alex Karp Thinks AI's Irresponsibly Oversold, Critiques OpenAI and Anthropic — Is He Right?
PLTR Palantir Technologies
FMP Stock News
Original source text
Palantir (NASDAQ:PLTR | PLTR Price Prediction) CEO Alex Karp has been making headlines for his heated rant on CNBC, critiquing OpenAI and Anthropic for how they’re selling AI. Indeed, it certainly feels like the wild west days as enterprises look to unlock value where possible from the leading AI models by using tokens in a way that’s not at all optimal.

The early scramble to spend money now (on tokens) while assessing value later might not seem logical, but in such a gold rush where earlier movers could unlock meaningful advantages, I do understand why some firms wouldn’t mind getting a bit ahead of their skis when it comes to spending on tokens.

As the trend of “tokenmaxxing” exhausts and naturally corrects itself, questions linger as to whether Mr. Karp’s frustrations are warranted and whether companies really are giving away their “alpha” when they run their proprietary data using models from frontier AI labs.

The “tokenmaxxing” era may have gone too far Indeed, it seems like Mr. Karp’s argument is that enterprises, like the government, should seek to own, rather than rent, AI compute. While I understand where the man is coming from, I’d argue that it doesn’t make a ton of sense for a firm to allocate a significant amount of CapEx to own the “means of production” when you consider the steep CapEx that goes into building out all the infrastructure and what’s lost by not using the absolute best model at any point in time.

Why spend on owning if it’s going to cost a fortune, you might not get the best model, and tokens are already collapsing in price, thanks in part to more efficient models and better hardware? While moving to on-prem AI data centers might make sense for some firms, I do think that the rise of the private cloud stands out as providing the best of both worlds.

Any way you look at it, the price of cutting off the frontier AI labs may be too high, even as tokens generate suspect value in these earlier innings. Perhaps deliberate token budgeting and diversifying across multiple models (as many firms are already doing) is the best way to go.

So, in short, AI might be oversold, but, then again, making models at the frontier doesn’t come cheap, either — just look at OpenAI’s financials. Given this, maybe it’s what has to be done to keep the lights on.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Palantir didn't make the cut. Grab the names FREE today.

Why renting AI compute is the way to go In any case, getting into the business of building data centers seems more expensive and riskier than just renting AI compute from the hyperscalers, especially given the market isn’t all too fond of the amount of CapEx they’ve been posting this year. Arguably, it makes more sense to own the infrastructure once firms are able to extract serious value from every token. In these earlier experimental changes, the costs of owning versus renting, I think, are way too high.

Any way you look at it, I really don’t understand Alex Karp’s argument when it comes to the cost argument, at least from the perspective of everyday enterprise customers that might not want to raise the bar on CapEx and get punished for it by public market investors.

In my view, the “alpha leak” warning might raise red flags, especially following an Apple (NASDAQ:AAPL) lawsuit that alleged OpenAI tried to steal trade secrets. Either way, the hyperscalers have private clouds, which should ease the concerns of those worried about surrendering “alpha” to the landlords of AI compute.

Any way you look at it, it’s clear that the days of tokenmaxxing might be coming to an end. And it’s the perfect solution as firms look to shift gears in a way that ROI is taken into consideration.

Indeed, when it comes to how tokens are being spent, it looks like things are naturally correcting and nothing extreme, such as committing significant CapEx to build something massive, especially as a non-tech firm with no expertise in the area. Outside of governments and maybe a few big-league financial institutions, I think well over 90-95% of businesses will find it’s more economical to rent compute from the likes of a hyperscaler. But, of course, that’s my humble opinion.

The bottom line Time will tell what the next market shift will be, but count me as a skeptic when it comes to Alex Karp’s case for owning the means of production rather than renting, especially at a time when we could see token costs collapse while closed-source intelligence skyrockets.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Palantir didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.
2026-07-14 16:15 27d ago
2026-07-14 10:10 27d ago
Meta Vs. Palantir: Meta Platforms' Deep Value Moats Crush Palantir's Hyper-Inflatated Multiple
PLTR Palantir Technologies
FMP Stock News
Original source text
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Meta Platforms (NASDAQ: META | META Price Prediction) and Palantir Technologies (NASDAQ: PLTR) both posted Q1 2026 results that widened an already yawning valuation gap. Meta ran its ad machine at scale while ramping AI infrastructure. Palantir kept doubling its U.S. commercial business and pushing multiples that pin the next decade of execution to the current share price.

Ad Dollars Compound While Palantir Sells Rule of 40 Meta pulled in $56.31 billion in revenue, up 33.08% year over year, with advertising alone at $55.02 billion and price per ad rising 12%. That is real pricing power on 3.56 billion daily users. Reported EPS of $10.44 was flattered by an $8.03 billion CAMT tax benefit worth $3.13 per share, so the underlying beat is smaller than the headline suggests.

Palantir grew revenue 84.71% to $1.63 billion, with U.S. commercial up 133%. Alex Karp led with a “Rule of 40 score has soared to 145%” boast, comparing Palantir to NVIDIA and Micron. The growth is real. The problem is the price tag attached to it.

Cash Machine Versus Story Multiple Lens Meta Palantir Trailing P/E 21 145 Price/Sales (TTM) 7 59 Operating margin 41.4% 31.6% 2026 capex $125 to $145 billion Minimal Meta is funneling a $125 billion-plus AI build through an insulated advertising monopoly, with Zuckerberg pitching “personal superintelligence to billions of people”. Palantir must convert Gotham, Foundry, and AIP wins into decades of clean compounding to grow into 88x forward earnings. Contracts remain terminable for convenience, and $201.6 million in quarterly stock-based comp keeps diluting the story.

The Next Test Is Capex Payback I want to see Meta’s Reality Labs $4.03 billion quarterly loss stabilize and its AI compute find external monetization. Prediction markets already price 84.5% odds Meta outvalues OpenAI at year-end, a useful sanity check. For Palantir, Polymarket clusters near-term outcomes at $129 with sharp probability drop-off above $138. Traders doubt the multiple can stretch further, even after guidance was raised to 71% annual growth.

Why I Would Own Meta and Rent Palantir At Most For me, Meta screens as the cleaner setup here. You get a 21x earnings multiple, a $26.25 billion buyback pace, and pricing power that already survived a 18.05% one-year drawdown. Palantir’s platform is genuinely differentiated, but paying 59x sales for software with lumpy government contracts asks too much. If you are a turnaround or momentum investor comfortable with 27% YTD volatility, a small Palantir exposure can still be defensible. My core capital sits with Meta.

Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.

Over 50,000 people already have, along with global giants like General Motors and POSCO.

Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.

Contact [email protected] for any questions or corrections.
2026-07-14 16:15 27d ago
2026-07-14 11:33 27d ago
Why Palantir Technologies Stock Popped Today
PLTR Palantir Technologies
FMP Stock News
Original source text
Palantir Technologies (PLTR +1.36%) stock gained 2.2% through 11:15 a.m. ET Tuesday on some earnings news -- not an earnings report, exactly, but an announcement that earnings will be reported.

After close of trading on Monday, Aug. 3, 2026, to be precise.

Image source: Palantir.

News that news will happen isn't really news (yet) As catalysts for a 2% stock price bump, this leaves something to be desired. By itself, it doesn't make sense that simply announcing an earnings date would add more than $6 billion to Palantir's market capitalization.

Regardless, investors are lining up today to prepare themselves for what Palantir might report three weeks from now.

Today's Change

(

1.36

%) $

1.77

Current Price

$

131.81

What will Palantir report? And what will Palantir report next month? According to the consensus forecasts of Wall Street's best and brightest, Palantir's Q2 report should show quarterly revenue growing 80% year over year to $1.8 billion, with earnings more than doubling to $0.35 per share.

Sales growing strong double-digits, and earnings growing even faster (which indicates improved profit margins) would, of course, be good news, and potentially enough to reverse the long downturn that's been dogging Palantir investors, and that has the stock losing 12% of its value over the past year, versus S&P 500 gains of 20%.

Longer-term, analysts see Palantir earning $1.48 per share, up nearly double from 2025 earnings. With Palantir stock valued at more than 142 times trailing earnings, even doubling earnings this year won't be quite enough to turn Palantir into a value stock. If Palantir reports stronger free cash flow than net earnings, though, that might change the picture.

My advice: Focus on free cash flow when the news comes out in August. That'll tell you if Palantir stock is finally cheap enough to buy.

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy.
2026-07-14 16:15 27d ago
2026-07-14 11:36 27d ago
Palantir's Ontology Edge Is Redefining AI Software Leadership
PLTR Palantir Technologies
FMP Stock News
Original source text
Key Takeaways PLTR's Ontology organizes enterprise data into an operational framework that becomes more valuable over time.Palantir delivered 85% revenue growth, 133% U.S. commercial growth and a 60% adjusted operating margin.PLTR combines rapid growth and profitability, distinguishing it from AI software peers. Palantir (PLTR - Free Report) is increasingly distinguishing itself through an advantage that extends well beyond artificial intelligence models. At the heart of its platform is the Ontology, which organizes enterprise data into a connected operational framework that customers can continuously build upon.

Years of deployments across hundreds of organizations have created deeply integrated systems that are difficult and time-consuming to replace. This accumulated implementation expertise, strengthened by Palantir’s forward-deployed engineering model and long-standing government security credentials, makes the platform more valuable with every deployment.

Unlike AI developers that primarily compete on models, Palantir monetizes the operational layer where AI is applied, allowing its software to retain value even as foundation models become increasingly commoditized.

Palantir vs. AI Software PeersPLTR’s competitive strengths are reflected in its financial performance. The company delivered 85% revenue growth in the first quarter of 2026, including an exceptional 133% increase in U.S. commercial revenues, while generating a 60% adjusted operating margin and a 53% GAAP net margin. Even leading AI software companies like Datadog (DDOG - Free Report) and Snowflake (SNOW - Free Report) struggle to match this combination of rapid expansion and profitability.

While DDOG and SNOW continue to benefit from AI demand, their growth rates remain significantly lower. By combining a durable software foundation with industry-specific expertise and superior execution, Palantir continues to separate itself from DDOG, SNOW and traditional enterprise software competitors.

PLTR’s Price Performance & EstimatesThe stock has declined 27% year to date compared with the industry’s 5% fall.

                                                          Image Source: Zacks Investment Research

From a valuation standpoint, PLTR trades at a forward price-to-sales ratio of 33.13X, well above the industry’s 4.08X. It carries a Value Score of F.

                                                                    Image Source: Zacks Investment Research

The Zacks Consensus Estimate for PLTR’s 2026 earnings declined over the past 60 days.

                                                                       Image Source: Zacks Investment Research

PLTR currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-07-14 16:15 27d ago
2026-07-14 10:56 27d ago
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
BMY Bristol-Myers Squibb
FMP Stock News
Original source text
Key Takeaways Bristol Myers Squibb's mezigdomide NDA for RRMM received FDA acceptance with a May 13, 2027, action date.BMY is advancing multiple CELMoD candidates and protein degrader programs across hematology and oncology.Bristol Myers Squibb's iberdomide NDA for RRMM has Priority Review with an Aug. 17, 2026, action date. Bristol Myers Squibb (BMY - Free Report) recently announced that the FDA has accepted its new drug application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM).

The regulatory body has granted a target action date of May 13, 2027 for this indication.

Mezigdomide is an oral cereblon E3 ligase modulator, or CELMoD, for the treatment of multiple myeloma.

It was developed using BMY’s targeted protein degradation platform (TPD), built over two decades.

BMY boasts a deep and promising pipeline. Key pipeline candidates with multi-billion-dollar potential are milvexian (Oral factor XIa inhibitor), admilparant (LPA1 antagonist), pumitamig (PD-L1 x VEGF-A bispecific antibody) and iberdomide & mezigdomide (oral CELMoD protein degraders).

BMY is the only drugmaker to have successfully developed and commercialized protein degrader therapies for multiple myeloma through its immunomodulatory drugs (IMiDs), which have become a standard of care for the disease.

The company is advancing a broad pipeline of investigational protein degraders using three complementary approaches — CELMoD agents, ligand-directed degraders (LDDs) and degrader antibody conjugates (DACs). By leveraging multiple degradation technologies, the company aims to target disease-causing proteins that were previously difficult to treat, expanding opportunities across hematology, oncology and other therapeutic areas.

Mezigdomide is also being evaluated in the ongoing phase III SUCCESSOR-1 study versus standard of care regimen in relapsed or refractory multiple myeloma.

BMY’s pipeline also includes iberdomide, an investigational, oral CELMoD, in combination with daratumumab, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma, and golcadomide, a potential first-in-class investigational CELMoD for lymphoma CELMoD.

The FDA has accepted a new drug application for iberdomide in combination with standard treatment (daratumumab and dexamethasone) for RRMM, granting Breakthrough Therapy Designation and Priority Review, with a target action date of Aug. 17, 2026.

BMY’s Competition in Oncology SpaceOncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space.  

The company competes with big pharma giants like Merck (MRK - Free Report) and Pfizer (PFE - Free Report) in this space.

The immuno-oncology space is dominated by pharma giant MRK’s blockbuster drug Keytruda (pembrolizumab).

Keytruda is approved for several types of cancer and alone accounts for around 55% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.    

Pfizer is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immune-oncology biologics that treat a wide range of cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, including lung cancer.

Pfizer’s position in oncology was strengthened with the addition of Seagen.

The company inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China.

BMY’s Price Performance, Valuation & EstimatesShares of Bristol Myers have gained 10% year to date compared with the industry’s growth of 3.3%.

Image Source: Zacks Investment Research

From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, shares currently trade at 9.58X forward earnings, higher than its mean of 8.61X but lower than the large-cap pharma industry’s 18.59X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 EPS has moved north to $6.32 from $6.30 in the past 60 days, while that for 2027 has moved north to $6.09 from $6.05 in the same time frame.

Image Source: Zacks Investment Research
2026-07-14 16:14 27d ago
2026-07-14 10:30 27d ago
Hynix Isn't Selling Shares to Cash Out. It's Funding a $26.5 Billion Factory Bet.
MU Micron Technology
FMP Stock News
Original source text
Given how many times most investors have seen it before, it would be easy to assume an insider or founder is just using the market's recent strength to cash in -- by getting out -- while valuations are high.

That's not the case here, though. Every penny of SK Hynix's (SKHY +19.36%) recent public offering is going into the company's war chest. Much of it's already earmarked, in fact, to capitalize on an opportunity that's going to continue growing for the foreseeable future. Here's what you need to know.

Image source: Getty Images.

SK Hynix in the spotlight It's possible you're regularly relying on its hardware without even realizing it. See, SK Hynix makes computer memory of all sorts, including data storage (NAND solid state drives), DRAM (your device's capacity to manage information and handle different tasks whenever it's turned on), and perhaps most notably right now, the high-bandwidth memory -- or HBM -- increasingly being used in artificial intelligence computing. Last year, the now-$1 trillion South Korean company turned $65 billion worth of revenue (up 47% year over year) into net income of nearly $29 billion. Granted, that was an unusually good year, boosted by a combination of soaring demand and limited supply, and subsequently, outstanding pricing power.

The underpinnings of this growth are still in place, though, and will be for a while. That's the ongoing proliferation of AI data centers, specifically the high-bandwidth memory they increasingly require. Rivals Micron Technology (MU +4.73%) and Samsung (SSNLF +0.00%) also make HBM, but not at the quality and scale of SK Hynix.

SK Hynix also has the benefit of being AI market-leading Nvidia's (NVDA +2.38%) preferred tech partner, which regularly pairs its AI processors with SK's memory chips. That's a big reason the company controls more than half of the HBM market, according to Counterpoint Research.

Now with even more cash in hand, SK Hynix is ready to become a fiercer competitor not only in the HBM market but also in the NAND and DRAM markets.

Plenty of constructive uses of the money It wasn't an initial public offering, for the record. A public offering? Yes. But not the company's first-ever issuance of stock in exchange for cash. SK Hynix first listed its shares in South Korea all the way back in 1996.

The recent fundraiser, rather, came from its first foray into the U.S. capital market, with American depository receipts. ADRs are simply tradable certificates representing foreign-listed tickers that would otherwise be difficult for U.S. investors to own. In this instance, every 10 shares of the U.S.-listed ADR represent one newly issued, South Korean-listed share of SK Hynix held in trust by the ADR's sponsor, Citigroup. Little else is different, though. SK Hynix received $26.5 billion in cash proceeds from American investors interested in investing in the company's growth potential.

That potential is jaw-dropping, too. Precedence Research predicts the HBM market alone is poised to grow at an average annual rate of 25% through 2035, when it will be worth nearly $70 billion per year.

And that's just high-bandwidth memory, to be clear. Mordor Intelligence expects the overall DRAM business to grow by nearly 15% per year through 2031, when it will annually be worth almost $250 billion. Most of this demand will come from artificial intelligence data centers.

So what's SK Hynix's plan for its recent $26.5 billion cash injection? Expand its capacity to meet this growing demand ... fast. It's already constructing a new foundry near Seoul, South Korea's Yongin Cluster; it's building an advanced packaging plant in Cheongju; and it intends to purchase multiple EUV (extreme ultraviolet) lithography machines used to manufacture semiconductors, just to name a few. These moves should not only maintain the company's position as one of the world's most important memory makers, but also help it remain the leading HBM name, positioning it perfectly to capitalize on the impending growth of this sliver of the AI data center infrastructure market.

Worth the inevitable volatility Like most other AI stocks, this one has rallied since 2023 (shortly after the launch of OpenAI's ChatGPT started what would evolve into a full-blown artificial intelligence revolution), and outright soared this year; the company couldn't have picked a better time to issue new shares. Aiming its fundraising efforts at U.S. investors is savvy, given how American investors are willing to pay a premium for a compelling opportunity like this one right now.

Today's Change

(

19.36

%) $

29.50

Current Price

$

181.85

Of course, this can -- and eventually will -- lead to a profit-taking-driven pullback. That's simply the norm for AI stocks.

Still, this stock's/ADR's current price and valuation aren't unreasonable where they stand right now, and would be outright bargains after any decent dip, especially given what awaits. Already sporting high profit margins, a recent report from DigiTimes suggests that high-bandwidth memory prices could more than double between now and 2027, yet still not quell growing demand. SK Hynix could easily outperform next year's analyst-projected earnings growth of 40%. And that's still just the beginning of what's expected to be a multiyear stretch of similar growth.

This might help convince you: The vast majority of analysts covering this stock still rate it as a strong buy, with a consensus price target that's more than 60% above its present price. That's not a bad way to start out a new trade.
2026-07-14 16:14 27d ago
2026-07-14 10:46 27d ago
Here's Why Micron (MU) is a Strong Growth Stock
MU Micron Technology
FMP Stock News
Original source text
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Micron (MU - Free Report) Micron Technology, Inc., headquartered in Idaho, has established itself as one of the leading worldwide providers of semiconductor memory solutions.

MU is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. MU has a Growth Style Score of A, forecasting year-over-year earnings growth of 791% for the current fiscal year.

12 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $14.82 to $73.86 per share. MU boasts an average earnings surprise of +21.1%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MU should be on investors' short list.
2026-07-14 16:14 27d ago
2026-07-14 10:56 27d ago
Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
ISRG Intuitive Surgical
FMP Stock News
Original source text
Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.
2026-07-14 16:14 27d ago
2026-07-14 11:51 27d ago
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
AMGN Amgen
FMP Stock News
Original source text
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© man_at_mouse / Getty Images

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology. Pfizer is monetizing its Seagen deal today. Amgen is defending a biosimilar cliff while spending to rebuild growth from scratch.

Padcev Carries Pfizer. Biosimilars Bite Amgen. Pfizer’s oncology franchise pulled in $3.83 billion, up 9% year over year, led by Seagen’s crown jewel Padcev at $591 million (+39%) on first-line urothelial share gains. Lorbrena jumped 37%, Orgovyx 43%, and total launched and acquired products grew 22% operationally. That is real commercial momentum.

Amgen’s story is bifurcated. IMDELLTRA soared 219% to $258 million and UPLIZNA jumped 188%, yet legacy supportive care crumbled. Prolia fell 34% to $727 million, XGEVA dropped 27%, and Enbrel slid 37% under Medicare Part D price setting. CEO Robert Bradway framed it optimistically, noting “16 brands achieving double-digit growth, enabling us to grow through expected patent expirations”. The math is tighter than the tone suggests.

Business Driver Pfizer Amgen Oncology engine Seagen ADCs (Padcev, Tukysa) BiTE platform (IMDELLTRA) Biggest drag COVID: Comirnaty -59% Prolia biosimilars -34% Revenue growth +5.4% +5.76% Monetizing Assets vs. Rebuilding a Base Albert Bourla said Pfizer is “off to a strong start in 2026” and singled out oncology and obesity as areas where he expects Pfizer to lead. That confidence rests on existing revenue streams already booking growth. Padcev’s Phase 3 EV-304 trial showed a 47% reduction in tumor recurrence, progression or death in MIBC patients, with a PDUFA target of August 17, 2026.

Amgen’s counter is capital-intensive. MariTide obesity trials, Xaluritamig in prostate cancer, and biosimilars for KEYTRUDA and OPDIVO all require years of spend before payback. Debt sits at $57.3 billion. Amgen is pivoting heavy capital into high-risk, early-stage platforms just to defend its baseline.

The Padcev PDUFA and MariTide Readouts Will Set the Tone I will be watching Padcev’s August 17 PDUFA decision, Elrexfio’s myeloma expansion, and whether Pfizer can hold its reaffirmed $59.5 to $62.5 billion revenue guide against a $1.5 billion generic headwind. For Amgen, MariTide Phase 3 readouts and the pace of Prolia erosion matter most. Any acceleration there pressures the $37.1 to $38.5 billion full-year guide.

Why I Lean Toward Pfizer for Oncology Alpha Personally, I lean Pfizer here. You are paying a forward P/E of 8 for a business collecting cash today from Seagen assets, versus 17 for Amgen’s rebuild story. The 7.07% dividend yield compensates holders during the wait. Amgen’s stock has run 14.1% YTD while Pfizer is flat at -0.07%, which is exactly why I find PFE more interesting now. Investors focused on the growth narrative who can tolerate biosimilar drag will find Amgen’s setup more compelling. If input costs stay volatile and MFN pricing tightens, the cheaper multiple and the working oncology franchise become more attractive on a relative basis.

Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.

Over 50,000 people already have, along with global giants like General Motors and POSCO.

Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.

Contact [email protected] for any questions or corrections.
2026-07-14 16:14 27d ago
2026-07-14 12:00 27d ago
Zillow Group, Inc. (Z, ZG) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Z Zillow
FMP Stock News
Original source text
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Zillow Group, Inc. ("Zillow" or the "Company") (NASDAQ: Z, ZG).

IF YOU SUFFERED A LOSS ON YOUR ZILLOW INVESTMENTS, CLICK HERE BEFORE AUGUST 10, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About? 
The complaint filed alleges that, between February 11, 2025 and May 7, 2026, Defendants failed to disclose to investors that: (1) Zillow's agreement with Redfin was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.

Charles Linehan, Esq.,

Glancy Prongay Wolke & Rotter LLP,

1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected] 

Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.  

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Glancy Prongay Wolke & Rotter LLP,  

1925 Century Park East, Suite 2100,

Los Angeles, CA 90067

Charles Linehan
Email:  [email protected] 

Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

SOURCE Glancy Prongay Wolke & Rotter LLP
2026-07-14 16:14 27d ago
2026-07-14 10:30 27d ago
Is MercadoLibre (MELI) a Buy as Wall Street Analysts Look Optimistic?
MELI MercadoLibre
FMP Stock News
Original source text
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about MercadoLibre (MELI - Free Report) .

MercadoLibre currently has an average brokerage recommendation (ABR) of 1.66, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 19 brokerage firms. An ABR of 1.66 approximates between Strong Buy and Buy.

Of the 19 recommendations that derive the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 68.4% and 5.3% of all recommendations.

Brokerage Recommendation Trends for MELI

Check price target & stock forecast for MercadoLibre here>>>

The ABR suggests buying MercadoLibre, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is MELI Worth Investing In?Looking at the earnings estimate revisions for MercadoLibre, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $40.97.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for MercadoLibre. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for MercadoLibre.
2026-07-14 16:14 27d ago
2026-07-14 11:36 27d ago
Can Cross-Border Trade Become MercadoLibre's Next Growth Pillar?
MELI MercadoLibre
FMP Stock News
Original source text
Key Takeaways MercadoLibre's cross-border GMV rose 68% year over year on an FX-neutral basis in Q1 2026.Free shipping, multi-seller carts, seller incentives and a China fulfillment center reduced friction.Argentina and Andean markets are adding growth as broader assortment supports the model's scale. MercadoLibre, Inc. (MELI - Free Report) is aggressively scaling its cross-border trade as a potential long-term growth driver. The company recorded impressive 68% year-over-year, foreign-exchange-neutral gross merchandise volume growth for the segment in the first quarter of 2026. This momentum indicates that international commerce is becoming a crucial operational layer alongside the core local marketplace.

The company believes it holds a unique position by connecting merchants in China and the United States with buyers across Latin America. Chinese suppliers, in particular, offer competitive prices, rapid product innovation and broad merchandise selection, helping MercadoLibre address growing consumer demand for affordability and assortment.

The business underwent meaningful changes during 2025. MercadoLibre simplified access to free shipping, introduced multi-seller shopping carts, expanded seller incentives and increased its presence in China, including opening its first fulfillment center there. These initiatives were designed to remove friction from the international drop-shipping model while improving execution and merchant relationships.

Growth is no longer concentrated in Mexico alone. Argentina and the Andean countries are contributing more meaningfully to cross-border trade growth, while markets such as Colombia and Peru benefit from broader product assortment where local seller networks are less developed.

MercadoLibre believes this model can become profitable as scale improves. By expanding product availability, improving delivery capabilities and strengthening merchant participation, cross-border trade is evolving into an increasingly important component of the company's marketplace strategy rather than simply an incremental international offering.

What the Latest Metrics Say About MercadoLibreMercadoLibre, which competes with Amazon.com, Inc. (AMZN - Free Report) and Sea Limited (SE - Free Report) , has seen its shares tumble 11.1% over the past six months compared with the industry’s 3.4% decline. While shares of Amazon have jumped 3.8%, those of Sea Limited have fallen 10.8% in the aforementioned period.
 

Image Source: Zacks Investment Research

From a valuation standpoint, MercadoLibre's forward 12-month price-to-earnings (P/E) ratio stands at 36.43, higher than the industry’s ratio of 21.94. The stock is also trading above its 12-month median level of 34.46.

MercadoLibre is trading at a premium to Amazon (with a forward 12-month P/E ratio of 25.97) and Sea Limited (22.29).

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for MercadoLibre’s current financial-year sales and earnings per share implies year-over-year growth of 39.7% and 4%, respectively. For the next fiscal year, the consensus estimate indicates a 26.6% rise in sales and 47% growth in earnings.
 

Image Source: Zacks Investment Research

MELI currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-07-14 16:14 27d ago
2026-07-14 10:30 27d ago
Is Sea Limited (SE) a Buy as Wall Street Analysts Look Optimistic?
SE Sea Limited
FMP Stock News
Original source text
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Sea Limited Sponsored ADR (SE - Free Report) .

Sea Limited currently has an average brokerage recommendation (ABR) of 1.38, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 20 brokerage firms. An ABR of 1.38 approximates between Strong Buy and Buy.

Of the 20 recommendations that derive the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 75% and 10% of all recommendations.

Brokerage Recommendation Trends for SE

Check price target & stock forecast for Sea Limited here>>>

The ABR suggests buying Sea Limited, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Should You Invest in SE?In terms of earnings estimate revisions for Sea Limited, the Zacks Consensus Estimate for the current year has declined 2.9% over the past month to $4.15.

Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Sea Limited. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, it could be wise to take the Buy-equivalent ABR for Sea Limited with a grain of salt.
2026-07-14 16:13 27d ago
2026-07-14 10:40 27d ago
Is Occidental Petroleum (OXY) Stock Undervalued Right Now?
OXY Occidental petroleum
FMP Stock News
Original source text
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.

One company value investors might notice is Occidental Petroleum (OXY - Free Report) . OXY is currently holding a Zacks Rank #2 (Buy) and a Value grade of A.

Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. OXY has a P/S ratio of 2.3. This compares to its industry's average P/S of 2.92.

Finally, our model also underscores that OXY has a P/CF ratio of 4.59. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. OXY's current P/CF looks attractive when compared to its industry's average P/CF of 4.98. Over the past 52 weeks, OXY's P/CF has been as high as 4.78 and as low as 3.32, with a median of 4.31.

Value investors will likely look at more than just these metrics, but the above data helps show that Occidental Petroleum is likely undervalued currently. And when considering the strength of its earnings outlook, OXY sticks out as one of the market's strongest value stocks.
2026-07-14 16:13 27d ago
2026-07-14 10:52 27d ago
The 1 Number That Sets the Record Straight on AI Chip Demand: $75 Billion
TSM Taiwan Semiconductor
FMP Stock News
Original source text
© Quality Stock Arts / Shutterstock.com

The Number: $75.25 Billion Chip stocks have been steering the market lately, and NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) remains at the center of the move. The number that tells the story is $75.25 billion. That is how much revenue NVIDIA generated from its Data Center segment in Q1 fiscal 2027, up 92% year over year. Those are the results, not guidance, and they account for the overwhelming share of NVIDIA’s $81.61 billion total quarterly haul. For investors trying to measure real AI chip demand, Data Center is the cleanest read.

What It Means The mix inside the number matters. Nvidia’s fiscal Q1 Data Center compute contributed $60.4 billion, up 77% year over year, while networking revenue reached a record $14.8 billion, up 199% year over year, reflecting demand for InfiniBand, Spectrum-X Ethernet and NVLink fabric tied to Blackwell 300 rack deployments. Hyperscalers accounted for roughly 50% of Data Center revenue. That puts the world’s largest cloud buyers directly behind the number investors are trying to decode.

Non-GAAP gross margin came in at 75.0%, and operating income reached $53.54 billion, up 147.4% year over year. Net income was $58.32 billion. Those items describe a business converting AI infrastructure orders into cash at scale, with $48.55 billion in free cash flow for the quarter.

NVIDIA traded at $221.54 at the filing on May 20, 2026. The stock is up 28.72% over the past year and 9.9% YTD.

Strategic Outlook Management guided Q2 FY2027 revenue to $91.0 billion, give or take 2%, with China Data Center compute revenue excluded, alongside a non-GAAP gross margin of 75.0%. Total supply-related commitments stand at $119.0 billion, signaling booked demand well beyond the current quarter. The board authorized an additional $80.0 billion in share repurchases and boosted its quarterly cash dividend from $0.01 to $0.25 per share. NVIDIA returned roughly $20.0 billion to shareholders in Q1 via buybacks and dividends.

Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.

CEO Jensen Huang described the AI buildout as “the largest infrastructure expansion in human history.” The read-through across the ecosystem is already showing up: Taiwan Semiconductor (NYSE:TSM) reported June 2026 net revenue of NT$442.68 billion, up 67.9% year over year, adding supply-side evidence of the same demand pull behind NVIDIA’s order book.

Bottom Line The $75.25 billion Data Center figure is the most concentrated readout on AI chip demand available in public filings. It shows hyperscaler orders, Blackwell 300 shipments and networking attach rates all scaling together, with margins holding at the mid-70s. For now, the signal is hard to miss: the AI capex cycle is still converting into revenue, margin, and cash.

The next test lands quickly: Taiwan Semiconductor reports full Q2 2026 results on July 16, 2026, with consensus at $3.83 EPS. Investors watching whether AI capex is accelerating or plateauing get their next data point later this week, and NVIDIA’s Q2 FY2027 report against the $91.0 billion revenue guide will close the loop.

Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.

Contact [email protected] for any questions or corrections.
2026-07-14 16:13 27d ago
2026-07-14 11:54 27d ago
TSMC's 68% Sales Surge Just Validated This Billionaire's $9.5 Billion Bet
TSM Taiwan Semiconductor
FMP Stock News
Original source text
The latest sales figures also reinforce one of Wall Street’s biggest hedge fund bets.

Billionaire’s AI ConvictionBillionaire investor Lewis Sanders, founder of Sanders Capital, owns approximately 28.1 million TSMC shares valued at about $9.5 billion, making the chipmaker the firm’s largest holding and accounting for roughly 11.3% of its equity portfolio.

The position reflects a high-conviction bet on the company at the heart of the AI semiconductor supply chain.

Even after TSMC’s strong rally over the past two years, Sanders has maintained the position as one of his firm’s largest investments, underscoring continued confidence in the long-term AI growth story.

AI Demand Remains StrongTSMC’s June sales report suggests that demand has remained resilient heading into earnings.

June revenue reached NT$442.68 billion, up 6.2% from May, while first-half sales climbed 35.6% year over year. The figures reinforce expectations that AI infrastructure spending by hyperscalers and semiconductor customers remains robust despite growing debate over whether the pace of AI investment can be sustained.

The earnings report, due Wednesday, is expected to provide greater insight into management’s outlook for AI-related demand, advanced packaging capacity and capital spending—three areas investors will closely watch for signs that the industry’s multiyear growth cycle remains intact.

Why Investors Are WatchingSanders isn’t alone in betting on TSMC. The chipmaker remains a favorite among several prominent hedge funds such as Fisher Asset Management, Coatue Management, Tiger Global Management and Viking Global Investors, reflecting its central role in supplying the world’s leading AI chip designers.

For investors, the latest sales report serves as another data point suggesting that, despite concerns about lofty AI valuations, the demand driving the sector’s biggest winners continues to hold up.

For Lewis Sanders and other long-term believers, Monday’s revenue update offered fresh support for a multibillion-dollar investment thesis that has so far paid off.

Photo by Sundry Photography via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-14 16:13 27d ago
2026-07-14 10:35 27d ago
Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?
ABT Abbott
FMP Stock News
Original source text
Key Takeaways Abbott is expected to report Q2 EPS of $1.28 on $12.48B in revenues, up 1.6% and 12% year over year.ABT may benefit from Core Lab, Cancer Diagnostics, cardiovascular devices and EPD, while Nutrition stays weak.ABT trades below its historical valuation despite recent share weakness ahead of its July 16 earnings report. Abbott Laboratories (ABT - Free Report) is slated to report its second-quarter 2026 results on July 16, before the opening bell.

The Zacks Consensus Estimate for the company’s second-quarter earnings per share (EPS) suggests 1.6% year-over-year growth to $1.28. The estimate has remained constant in the past 60 days. The consensus mark for second-quarter revenues currently stands at $12.48 billion, implying a 12% increase over the prior-year period. 

Image Source: Zacks Investment Research

In the trailing four quarters, the company topped earnings estimates twice and broke even on two occasions, the average surprise being 0.42%.

Image Source: Zacks Investment Research

Q2 Earnings Whispers for AbbottPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.

Earnings ESP: Abbott has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank:The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.

Factors Likely to Have Shaped ABT’s Q2 PerformanceDiagnosticsWithin this segment, Abbott may have delivered mixed performance in the second quarter. Rapid and Molecular Diagnostics are likely to have continued to face reduced demand for respiratory virus testing. At the same time, steady demand for the Core Lab diagnostic tests may have been a tailwind, with strong performance across the United States, Europe and Latin America.

Following the acquisition of Exact Sciences, Abbott added the Cancer Diagnostics business, expanding into one of the fastest-growing areas of healthcare. We assume the division to have favorably impacted the quarter’s results, driven by the Cologuard colorectal cancer (CRC) test momentum and contributions from the international markets.

A positive development in the quarter was the American Cancer Society’s updated CRC screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred non-invasive screening options for adults aged 45 and older who are at average risk. This is expected to have positively boosted adoption trends and revenues.

The Zacks Consensus Estimate anticipates Diagnostics revenues to increase 41.6% year over year.

Established Pharmaceutical Products (“EPD”)The segment is expected to have maintained its growth momentum in key emerging markets, supported by favorable long-term health care, economic and demographic trends, with a broad product offering across five therapeutic areas. The biosimilars portfolio, which has expanded to include several market-leading oncology therapies, may have been a positive driver as well for the segment’s top line.

Going by the Zacks Consensus Estimate, EPD revenues are likely to grow 6.6% from the prior-period levels.

Medical DevicesAbbott’s cardiovascular businesses are expected to have been the biggest contributor to Medical Devices’ top line in the second quarter of 2026.

Electrophysiology performance may have been boosted by contributions from the Volt and TactiFlex Duo pulsed field ablation (PFA) catheters. Rhythm Management likely continued to outpace the market, driven by the Aveir leadless pacemaker. Heart Failure business results may have benefited from the Heart Assist Devices portfolio.

In Vascular, the company secured FDA clearance and CE Mark for its next-generation Ultreon 3.0 Software in the quarter, bringing coronary imaging and AI-automated insights together in one system. The enhanced coronary portfolio likely contributed positively to the quarter’s results.

In Neuromodulation, Abbott’s rechargeable spinal cord stimulation device Eterna may have continued to see strong international adoption trends.

Further, the Diabetes Care business may have regained growth momentum following the easing of temporary headwinds, including a delay in the international tender renewal process and a challenging prior-period comparison. 

The Zacks Consensus Estimate expects Medical Devices revenues to increase 8.5% year over year.

NutritionThe segment is expected to have faced revenue pressure in the second quarter, as Abbott continues to transition toward a more sustainable balance between price and volume-driven growth. Sales volumes across both pediatric and adult nutritional product portfolios in the United States and internationally may have been lower. Although management reported early progress from these strategic actions in the previous quarter, it is yet to fully materialize.

The Zacks Consensus Estimate indicates Nutrition revenues will decline 4.3% year over year.

Abbott’s Peers Reporting Next WeekQuest Diagnostics (DGX - Free Report) is set to report second-quarter 2026 results on July 23, before the opening bell. The company’s Diagnostic Information Services segment is expected to have maintained its growth momentum, supported by organic growth across the physician, hospital and consumer channels. Contributions from recent acquisitions may have been a key driver. Productivity gains from the company’s automation and AI initiatives are likely to have favored the bottom line.

Thermo Fisher (TMO - Free Report) is also slated to report its 2026 second-quarter results before the market opens on July 23. Strength in the bioproduction and clinical research business, and the research and safety market channel may have supported the pharma and biotech end-market performance. Several recently launched high-impact innovations may have lifted revenues. The continued adoption of accelerated drug development offering is likely to have translated to share gain in its clinical research business.

ABT’s Price Performance & ValuationIn the three months ended June 30, Abbott shares have dropped 11.4%, underperforming the industry’s 10.1% decline. 

Image Source: Zacks Investment Research

In terms of valuation, Abbott trades at a forward five-year Price/Earnings (P/E) of 15.93X, lower than its median of 23.28X and 16.21X industry average.

Image Source: Zacks Investment Research

EndnoteAbbott is well-positioned to benefit from strength across several of its key businesses in the second quarter of 2026, including Core Lab Diagnostics, EPD and Electrophysiology. The newly added Cancer Diagnostics portfolio is also expected to have contributed. Nutrition may have continued to navigate the near-term impact of its pricing and volume transition, with the benefits of these strategic actions expected to build over time. In the trailing four quarters, Abbott beat earnings estimates twice and came in line on two occasions.

Despite its recent underperformance, ABT is trading at a relatively cheaper valuation. Given Abbott’s strong fundamentals and diversified growth drivers, we believe existing shareholders should continue to retain their positions to enjoy long-term gains.
2026-07-14 16:13 27d ago
2026-07-14 10:30 27d ago
Is Lilly Stock On Track To Hit $2,090?
LLY Eli Lilly & Co
FMP Stock News
Original source text
A Mounjaro KwikPen injection pen is seen in front of the Eli Lilly logo displayed on a screen in this illustration photo in Athens, Greece, on March 1, 2026. (Photo by Nikos Pekiaridis/NurPhoto via Getty Images)

NurPhoto via Getty Images

This article was written by Doug Nathman, with research by his team at Trefis.

With a share price of $1,182, Eli Lilly (LLY) is positioned for about 76% potential growth over the next three years in a conservative scenario. This projection is significant enough to warrant an examination of its sources. While revenue growth plays a crucial role, the valuation multiple also plays a critical part. Here’s the foundational operational reality of the calculations:

Amidst the global attention on two major blockbuster drugs, an alternative division of the business is displaying impressive growth. The latest quarter saw Lilly's immunology, oncology, and neuroscience treatments collectively achieving a year-over-year growth of 160%. This underappreciated sector hints at strength beyond merely the leading incretin narrative.

Such diversification guarantees a baseline, but the upper limit is primarily dictated by the cardiometabolic segment. The contributions from Mounjaro and Zepbound alone generated $6.7 billion in fresh growth this quarter, positioning revenue as the principal lever.

LLY Stock Key Fundamentals

Trefis

Understanding The CalculationThree estimates are pivotal in determining the potential upside. Revenue is anticipated to grow at a rate of 30% per year over three years, which is purposefully under the current rate of 47% due to the likelihood that such rapid acceleration won’t maintain over a three-year period. The net margin is projected to decline from 35% to 32% as the latest LTM returns to the historical average. Furthermore, the multiple has some adjustments to make, which are not beneficial for the company. Currently, LLY's P/E stands at 42.1x, which is below its average of 71.1x over three years. In this scenario, it is further adjusted down to 37.4x, as a decelerated growth rate does not justify even the current multiple.

MORE FOR YOU

When these three elements are combined, earnings increase from $25.3B to approximately $49.9B, which is a 98% increase. Applying the reduced multiple to this figure results in a stock price around $2,091, representing just 76% growth from the current price. The multiple reduces its impact before earnings influence the share value.

Is LLY Capable Of Achieving This?A new sales avenue may introduce unaccounted growth beyond the existing pharmaceutical pipeline. The introduction of Lilly Employer Connect, a platform for businesses to directly offer obesity medications, could provide a gradual impact starting in late ’26 with a rise in participation anticipated for ’27.

What Could Hinder This Progress?The major concern raised in the call revolves around pricing rather than demand. Management foresees price pressures in the low to mid-teens throughout the full year. This suggests that the most advantageous phase of the cycle may be waning.

Considering An Investment In LLY At The Current Price?Investors are investing in reliable growth rather than an immediate re-evaluation or extraordinary margin improvement. The expectation is that revenue continues to advance at a rate akin to projections; should it falter, the calculations could become less favorable. Additionally, a cyclical note: the current LTM figures emerge from a peak rather than a stable long-term rate. A regression to the three-year norm could reduce the earnings foundation before the other calculations have a chance to materialize.

The newly established Lilly Employer Connect channel offers a tangible avenue for increased volume, but may not completely counterbalance the pricing challenges.

Should You Consider Investing In Eli Lilly?For an alternative perspective on LLY, refer to our recent article The Wide Divide Ahead For Eli Lilly Stock.

Making a meticulous three-year evaluation of a single stock is still a concentrated risk, given that historical volatility evident in previous market downturns indicates. Investors who construct such analyses on singular equities often desire a similar analytical framework across a diversified portfolio, both for consistency and because even the most apparent single-stock rationale can falter due to factors not envisioned in the calculations.

Should your interest lie in exposure to the healthcare sector as a whole rather than focusing solely on this one entity, healthcare ETFs like XLV can cover that specific sector. Broadening beyond an individual sector, through a quality-oriented portfolio that encompasses the entire market, introduces the approach outlined below.

The Trefis High Quality (HQ) Portfolio merges analytical precision with a forward-thinking outlook across 30 stocks, employing a consistent selection process along with sizing and re-balancing strategies aimed at achieving upside while mitigating the risks tied to single-stock investments discussed earlier.

By selecting 30 high-conviction stocks, the HQ approach has historically outperformed a benchmark that integrates the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.
2026-07-14 16:13 27d ago
2026-07-14 10:56 27d ago
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
LLY Eli Lilly & Co
FMP Stock News
Original source text
Key Takeaways JNJ gained about 25% year to date on strong earnings, regulatory wins and higher guidance. IHE lists Johnson & Johnson as its largest holding, offering focused pharma exposure. ETFs like XLV include JNJ among top holdings, providing broader healthcare diversification. Johnson & Johnson (JNJ - Free Report) , a healthcare behemoth with a market cap exceeding $600 billion and a portfolio spanning pharmaceuticals and medical devices, has delivered a stellar year-to-date surge of approximately 24.5%. This performance notably outpaces the S&P 500's roughly 10% rise, effectively doubling the broader market's return. 

This dramatic performance might immediately push investor spotlight toward the company, especially against the backdrop of its latest announcement of the historic U.S. FDA approval of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform — a first-of-its-kind cardiac ablation system.

While this unrelenting corporate momentum might entice market participants to increase their stakes heavily in JNJ stock, investing in targeted healthcare exchange-traded funds (ETFs) that hold the company offers a more diversified and potentially less risky approach.

While JNJ's success is compelling, investing in healthcare ETFs that hold the stock offers a more prudent strategy for investors seeking diversified exposure to the sector's growth.

But before exploring these ETFs, it's essential to understand what propelled JNJ's exceptional run and whether the momentum can continue. We'll then examine why healthcare ETFs represent a safer vehicle to capture JNJ’s growth rather than investing in JNJ directly.

What Fueled JNJ’s 24% Surge?Johnson & Johnson's market-beating outperformance is a direct byproduct of its stellar underlying financials and regulatory wins. A primary catalyst that boosted the stock is undoubtedly its robust first-quarter 2026 results. JNJ delivered an impressive 9.9% year-over-year revenue jump to $24.1 billion, comfortably beating Wall Street’s consensus estimates and prompting management to raise its full-year guidance midpoints to $100.8 billion in sales and $11.55 in adjusted earnings per share.

Supporting this financial engine is a steady stream of clinical triumphs. In June, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval for the expanded use of Tecvayli (teclistamab) in multiple myeloma. This followed an FDA label expansion in May for Tremfya (guselkumab), which now includes clinical evidence of inhibiting structural joint damage in adults with active psoriatic arthritis. 

These regulatory milestones demonstrate that JNJ is successfully expanding the commercial footprint and clinical advantage of its key oncology and immunology portfolios, thereby strengthening its competitive moat and further boosting investor confidence.

Investors also reacted optimistically to JNJ’s aggressive long-term growth commitments. Last month, the company announced a massive capital expenditure of more than $1 billion to scale its Vision business operations in Jacksonville, FL. Aimed at drastically scaling production for its ACUVUE contact lenses, this project is part of a broader $55 billion pledge to U.S. manufacturing and R&D through 2029.

Will JNJ Continue to Rally?Looking ahead, several fundamental drivers are positioned to help JNJ sustain its aggressive momentum over the next few quarters. 

The company possesses an incredibly robust late-stage clinical pipeline, with its Innovative Medicine segment boasting over 20 novel therapies slated for regulatory filings, along with over 50 product expansions by 2030. This ensures a steady stream of prospective revenue growth.

The accelerating volume of global elective surgical procedures directly feeds the adoption rates of its specialized MedTech robotic systems, which should keep its operational margins elevated. 

Together, these factors should continue to boost JNJ’s momentum in the days ahead, with the high end of its price target estimates, offered by 24 analysts, pinned at $298, reflecting an upside of 16% from its current price level, over the short-run.

Why Healthcare ETFs Are the Smarter PlayWhile JNJ is a powerhouse healthcare stock, pivoting to healthcare ETFs is a highly prudent choice because it offers exposure to the structural growth catalysts of the broader healthcare sector, avoiding the risk of single-stock investment.  

Relying exclusively on JNJ exposes investors to localized corporate vulnerabilities, such as its recent multi-billion-dollar talc litigation settlements or the intense biosimilar competition threatening to erode margins on its immunology drug, STELARA. 

The stock’s valuation of over 20X forward earnings is considered slightly expensive compared to the industry average of 18.5X. 

On the contrary, by choosing an ETF where JNJ sits prominently in the top 10 holdings, an investor can effectively gain from JNJ’s profit while also leveraging the fund’s broader basket to absorb the blow if unexpected pipeline failures occur. Powerful secular tailwinds, such as rapidly aging global demographics and the widespread integration of AI in clinical diagnostics, can insulate investor portfolio from localized corporate missteps of a single stock.

JNJ-Heavy Healthcare ETFs to Buy NowConsidering the aforementioned discussion, investors looking to maximize exposure to JNJ's operational boom through a diversified lens can add the following healthcare ETFs to their portfolio: 

iShares U.S. Pharmaceuticals ETF (IHE - Free Report)

This fund, with net assets worth $1.43 billion, offers exposure to 56 U.S. companies in the pharmaceuticals sector. JNJ holds the first spot in this fund, with 22.36% weightage, while Eli Lily (LLY - Free Report) holds the second spot with 21.71% weightage. 

IHE has surged 17.9% year to date. The fund charges 38 basis points (bps) in fees and has traded at a volume of 0.09 million shares in the last trading session. It holds a Zacks ETF Rank #2 (Buy). 

State Street Health Care Select Sector SPDR ETF (XLV - Free Report)

This fund, with assets under management worth $41.51 billion, offers exposure to 60 companies in the pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology industries. LLY holds the first spot in this fund with 16.16% weightage, while JNJ holds the second spot with 10.63% weightage. 

XLV has risen 4.3% year to date. The fund charges 8 bps in fees and has traded at a good volume of 6.88 million shares in the last trading session. It sports a Zacks ETF Rank #1 (Strong Buy). 

Vanguard Health Care Index Fund ETF (VHT - Free Report)  

This fund, with net assets worth $17.8 billion, offers exposure to 429 companies that manufacture health care equipment and supplies or that provide health care-related services, and companies that are primarily involved in the research, development, production, and marketing of pharmaceuticals and biotechnology products. LLY holds the first spot in this fund, with 13.99% weightage, while JNJ holds the second spot with 8.44% weightage. 

VHT has risen 5.5% year to date. The fund charges 9 bps in fees and has traded at a volume of 0.16 million shares in the last trading session. It sports a Zacks ETF Rank #1. 
 
2026-07-14 16:13 27d ago
2026-07-14 11:01 27d ago
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
DHR Danaher
FMP Stock News
Original source text
Wall Street expects a year-over-year increase in earnings on higher revenues when Danaher (DHR - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 21. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis industrial and medical device maker is expected to post quarterly earnings of $1.83 per share in its upcoming report, which represents a year-over-year change of +1.7%.

Revenues are expected to be $6.08 billion, up 2.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.38% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Danaher?For Danaher, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.07%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination makes it difficult to conclusively predict that Danaher will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Danaher would post earnings of $1.94 per share when it actually produced earnings of $2.06, delivering a surprise of +6.19%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Danaher doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
2026-07-14 16:12 27d ago
2026-07-14 11:01 27d ago
Is RTX Strengthening Its Position in the Electronic Warfare Market?
RTX RTX Corporation
FMP Stock News
Original source text
Key Takeaways RTX is strengthening its electronic warfare position with advanced attack, sensing and mission systems.Next Generation Jammer Mid-Band disrupts radar, communications and air defenses across extended ranges.RTX's defense ties position it to benefit from sustained electronic warfare investment. RTX Corporation (RTX - Free Report) continues to strengthen its position in the electronic warfare (EW) market through its portfolio of advanced electronic attack, sensing and mission systems that support modern military operations. As armed forces increasingly invest in technologies that can detect, disrupt and counter sophisticated threats, the company remains well positioned to benefit from growing demand for next-generation EW capabilities across the United States and allied nations.

One of RTX's key offerings is the Next Generation Jammer Mid-Band (NGJ-MB), an advanced airborne electronic attack system developed for the U.S. Navy's E/A-18 Growler aircraft. The system is designed to disrupt enemy radar, communications and air-defense networks while enabling operators to engage multiple threats simultaneously over extended ranges. RTX's broader electronic warfare portfolio also includes advanced sensors, radar and mission systems that enhance situational awareness, survivability and mission effectiveness across a range of defense platforms.

The global electronic warfare market is expected to witness steady growth as rising geopolitical tensions, increasing defense budgets and rapid advancements in military technology encourage countries to modernize their defense capabilities. Electronic warfare has become a critical element of modern defense strategies as militaries seek to improve their ability to detect, deceive and counter increasingly sophisticated threats across multiple domains.

With its established electronic warfare technologies, diversified defense portfolio and long-standing relationships with the U.S. Department of Defense and allied nations, RTX appears well positioned to benefit from sustained investments in this market.

Other Electronic Warfare Stocks to WatchOther aerospace and defense companies strengthening their presence in the electronic warfare market are discussed below:

L3Harris Technologies (LHX - Free Report) : L3Harris offers a broad portfolio of electronic warfare systems, including the Viper Shield electronic warfare suite, the AN/ALQ-214 Integrated Defensive Electronic Countermeasures system and the Next Generation Jammer-Low Band, supporting air, land and maritime missions.

Lockheed Martin (LMT - Free Report) : Lockheed Martin develops advanced electronic warfare and electronic surveillance solutions for U.S. and allied defense forces. Its portfolio includes next-generation open-architecture electronic warfare systems designed to improve protection against evolving airborne and naval threats.

The Zacks Rundown for RTXShares of RTX have surged 32% in the past year against the industry’s 0.1% decline.

Image Source: Zacks Investment Research

The company’s shares are trading at a discount on a relative basis, with its forward 12-month Price/Earnings being 27.07X compared with its industry’s average of 32.84X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for RTX’s 2026 and 2027 earnings has moved north over the past 60 days.

Image Source: Zacks Investment Research
2026-07-14 16:12 27d ago
2026-07-14 10:43 27d ago
5 Stocks Most Impacted by JPMorgan's Earnings
MS Morgan Stanley
FMP Stock News
Original source text
© Chris Hondros / Getty Images News via Getty Images

JPMorgan kicked off Q2 2026 earnings season this morning with a blowout earnings report that reset expectations for the entire financial sector. The bank posted $7.70 in diluted EPS versus $5.80 expected and $57.35 billion in revenue, powered by a $4.6 billion Visa share exchange gain and a 27% surge in Commercial & Investment Bank revenue. Jamie Dimon flagged IB fees up 30% to the highest level since 2021 and Markets revenue up 35%.

That combination of trading strength, capital markets reopening, and resilient consumer credit is the read-through driving peer stocks today. Here are the five names most exposed to JPMorgan’s tone-setting report, ranked by the size and directness of the impact.

1. Goldman Sachs (GS) Goldman Sachs (NYSE:GS | GS Price Prediction) is the purest read-through, and it delivered its own bombshell alongside JPM. Goldman posted EPS of $20.98 versus $14.54 expected, a 44.27% beat and its fifth straight beat. Global Banking & Markets revenue jumped 53% to $15.52 billion, with Equities up 72% and Equity Underwriting up 130%. CEO David Solomon said “Momentum has accelerated throughout our businesses… we expect this flywheel of activity to continue.”

Shares were down 0.88% intraday to $1,045.91 despite the beat, suggesting expectations were already elevated after a 20.12% YTD run. The forward catalyst is backlog conversion: management noted the IB backlog grew again versus Q1.

2. Bank of America (BAC) Bank of America (NYSE:BAC) has the closest business mix to JPMorgan, and it also reported this morning. EPS came in at $1.21 versus $1.12 expected, with Equities S&T up 70% to $3.62 billion and investment banking fees up 50%. Net interest income rose 9% YoY, and credit metrics improved with the net charge-off ratio dropping to 0.47% from 0.55%.

Brian Moynihan called it “one of our strongest quarters to date” and noted “pipelines remain strong, and commercial borrowing has picked up.” Shares rallied 2.06% to $60.73, validating the universal-bank thesis JPM anchored.

Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.

3. Morgan Stanley (MS) Morgan Stanley (NYSE:MS) has not yet reported Q2, which makes today’s peer earnings reports a direct sentiment catalyst. The stock is up 4.55% to $231.16, the largest move among the five names. Morgan Stanley’s Q1 already showed 27.1% ROTCE, Advisory up 74%, and $118.4 billion in wealth net new assets. With JPM’s IB fees at their highest since 2021 and Goldman signaling a flywheel, MS’s advisory-heavy franchise inherits the same tailwind. Ted Pick previously described the firm as reporting “a record quarter”, and the read-through raises the bar again.

4. Wells Fargo (WFC) Wells Fargo (NYSE:WFC) is the closest analog to JPM’s core banking franchise, particularly on NII and consumer credit. Shares rose 0.63% to $88.22 as JPM’s 10% NII growth and stable credit card charge-offs of 3.33% supported Wells’ outlook. Wells guided full-year 2026 NII to roughly $50 billion, and its Q1 net interest margin already compressed to 2.47% from 2.67%. The macro backdrop helps: FRED credit card delinquencies eased to 2.92%, and retail sales hit $763.7 billion in May, up 0.9% month over month. WFC remains down 4.92% YTD, so a positive read-through matters most here.

5. Visa (V) Visa (NYSE:V) is the payments proxy for JPM’s consumer spending commentary. Shares climbed 2.52% to $357.75 after JPM highlighted Card Services and Auto revenue up 12% and card annual fees up more than 30%. Visa’s most recent quarter showed payments volume up 8% and cross-border volume up 11%, and JPM’s disclosure that Chase will become the new Apple Card issuer roughly 24 months from December 2025 reinforces network volumes. Ryan McInerney described Visa as “a payments hyperscaler” driven by resilient consumer spending, the exact theme JPM validated today.

Conclusion Three themes anchor today’s cross-company read-through: capital markets have decisively reopened (GS, MS, BAC benefit most), consumer credit is stabilizing rather than deteriorating (WFC, BAC, V), and buyback capacity remains robust, with JPM authorizing a fresh $50 billion program. The primary uncertainties Dimon flagged, “geopolitical tensions and wars, sticky inflation, large global fiscal deficits and elevated asset prices,” remain the swing factors. With Morgan Stanley and Wells Fargo still to report, today’s earnings set a high bar that either extends the sector rally or exposes crowded positioning.

Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.

Contact [email protected] for any questions or corrections.
2026-07-14 16:12 27d ago
2026-07-14 10:00 27d ago
Intuit Inc. (INTU) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
INTU Intuit
FMP Stock News
Original source text
Law Offices of Howard G. Smith announces an investigation on behalf of Intuit Inc. (“Intuit” or the “Company”) (NASDAQ: [url="]INTU[/url]) investors con
2026-07-14 16:12 27d ago
2026-07-14 12:00 27d ago
Bronstein, Gewirtz & Grossman LLC Urges Intuit Inc. Investors to Act: Class Action Filed Alleging Investor Harm
INTU Intuit
FMP Stock News
Original source text
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Intuit Inc. (NASDAQ: INTU) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intuit securities between August 22, 2025 and May 20, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/INTU.

Intuit Case Details

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:
      (1)   they had overstated Intuit’s competitive advantages and growth, as well as the overall strength and sustainability of its business model and operations;
      (2)   in reality, Intuit was losing significant business in its tax-related business, particularly in its TurboTax business, as a result of, inter alia, increasing competitive and pricing pressures;
      (3)   accordingly, Intuit’s previously issued FY 2026 TurboTax revenue growth guidance was unreliable and/or unrealistic; and
      (4)   as a result, Defendants’ public statements were materially false and misleading at all relevant times.

What's Next for Intuit Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/INTU. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Intuit you have until September 8, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Intuit Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Intuit Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.
2026-07-14 16:12 27d ago
2026-07-14 12:07 27d ago
Portnoy Law Firm Announces Class Action on Behalf of Intuit, Inc. Investors
INTU Intuit
FMP Stock News
Original source text
LOS ANGELES, July 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Intuit, Inc., (“Intuit” or the "Company") (NASDAQ: INTU) investors of a class action on behalf of investors that bought securities between August 22, 2025 and May 20, 2026, inclusive (the “Class Period”). Intuit investors have until September 8, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/intuit-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The Intuit class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) they had overstated Intuit’s competitive advantages and growth, as well as the overall strength and sustainability of its business model and operations; (ii) in reality, Intuit was losing significant business in its tax-related business, particularly in its Turbo Tax business, as a result of, among other things, increasing competitive and pricing pressures; and (iii) accordingly, Intuit’s previously issued 2026 TurboTax revenue growth guidance was unreliable and/or unrealistic.

On May 20, 2026, during pre-market hours, Reuters published an article entitled “Intuit to cut 17% of global jobs to streamline operations, memo shows,” allegedly reporting that Intuit “is laying off about 17% of its workforce, or about 3,000 employees worldwide.”  On this news, the price of Intuit stock dropped nearly 4%, according to the complaint.

Later that day, during post-market hours, Intuit issued a press release announcing its fiscal third quarter 2026 results, allegedly reporting weak Q3 2026 tax season revenue, including that TurboTax revenue grew by only 7% year-over-year versus consensus estimates of at least 8% revenue growth.  The Intuit class action lawsuit further alleges that on an accompanying conference call that day, Sasan K. Goodarzi, Intuit’s Chairman and CEO, disclosed that TurboTax online paying units were expected to grow by only 2% as total Internal Revenue Service filers were expected to decline by approximately 30 basis points, representing the “most significant industry-wide contraction since the post-COVID tax season.”  On this news, the price of Intuit stock dropped over 20%, according to the complaint.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising
2026-07-14 16:12 27d ago
2026-07-14 09:04 27d ago
Which High-Yield ETF Is a Better Buy in 2026: Vanguard VYM vs iShares HDV?
AVGO Broadcom
FMP Stock News
Original source text
Both the Vanguard High Dividend Yield ETF (VYM 0.29%) and the iShares Core High Dividend ETF (HDV 0.73%)serve as core options for investors seeking income from U.S. dividend-paying stocks.

The Vanguard High Dividend Yield ETF offers broader market diversification and a lower expense ratio, whereas the iShares Core High Dividend ETF provides a more concentrated portfolio with a higher trailing distribution yield.

So while both ETFs share the primary goal of providing higher-than-average yields, they differ significantly in portfolio breadth, sector concentration, and cost structures, making each suitable for different types of dividend-focused strategies.

Here’s all you need to know to help you decide which ETF to invest in.

Snapshot (cost & size)MetricHDVVYMIssueriSharesVanguardShare price$27.90 (as of 2026-07-14)$160.8 (as of 2026-07-14Expense ratio0.08%0.04%1-yr total return (as of 2026-07-13)22.2%20.3%Dividend yield2.8%2.3%Beta0.530.73AUM$14B$96.1BBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Performance & risk comparisonMetricHDVVYMMax drawdown (5 yr)(15.40%)(15.90%)Growth of $1,000 over 5 years (total return as of 2026-07-14)$1,717$1,774What's insideThe Vanguard High Dividend Yield ETF tracks a broad index of 605 stocks, providing expansive diversification across the U.S. market. The portfolio is balanced between financials (19.6%), technology (16.9%), and industrials (13.9%). Its largest positions include Broadcom (AVGO +2.30%) at 8.51%, JPMorgan Chase & Co (JPM +2.10%) at 3.14%, and Exxon Mobil (XOM +0.27%) at 2.53%. The ETF was launched in 2006. Vanguard High Dividend Yield ETF has paid $3.63 per share over the trailing 12 months, which on its current price works out to a 2.30% yield.

iShares Core High Dividend ETF (HDV 0.73%) holds only 75 stocks that meet specific yield and sustainability criteria. The fund leans heavily into defensive sectors, with consumer defensive and healthcare at 24.2% and 23.5%, respectively. Key holdings include Exxon Mobil (XOM +0.27%) at 7.3%, AbbVie (ABBV 1.23%) at 6.32%, and Chevron (CVX 0.15%) at 5.7%. The ETF was launched in 2011. iShares Core High Dividend ETF has paid $0.79 per share over the trailing 12 months, which works out to a 2.80% yield at current price.

For more guidance on ETF investing, readers can view the full guide at this link.

What this means for investorsThe Vanguard High Yield ETF and the iShares Core High Dividend ETF are popular ETFs among income investors.

VYM tracks the FTSE High Dividend Yield Index. The methodology is simple: It ranks U.S. dividend-paying stocks by their forecasted 12-month yield and includes the top 50% of the market, excluding Real Estate Investment Trusts, or REITs. Because it is heavily market-cap-weighted, large companies often make it to the top, and they’re also often financially strong.

HDV follows a very different set of criteria for selecting stocks. It tracks the Morningstar Dividend Yield Focus Index, which screens for companies with strong financial health and "economic moats" using Morningstar's proprietary credit risk metrics. That filters out companies with weak fundamentals and restricts the index to the top 75 highest-yielding stocks.

VYM Total Return Level data by YCharts

That makes VYM a highly diversified ETF with steady income, providing solid long-term growth potential at incredibly low cost. HDV is a more defensive fund that may have a smaller downside in down markets, thanks to its heavy tilt toward consumer staples and healthcare. Although its top three holdings include two energy stocks, both ExxonMobil and Chevron are among the top dividend-paying companies in the energy sector.

The portfolio composition and diversification are important factors to consider when selecting between the two ETFs. Or you could own some shares of both to earn steady, regular dividend income in 2026 and beyond.

JPMorgan Chase is an advertising partner of Motley Fool Money. Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Broadcom, Chevron, JPMorgan Chase, and Vanguard High Dividend Yield ETF. The Motley Fool has a disclosure policy.
2026-07-14 16:12 27d ago
2026-07-14 09:24 27d ago
AI’s Biggest Winners Are Creating Its Biggest Losers. Here’s What It Means for Investors
AVGO Broadcom
FMP Stock News
Original source text
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The AI investment cycle has become one of the most profitable technology booms in history. Every week seems to bring another report of record chip sales, expanding data center budgets, or larger capital spending plans from the world’s biggest technology companies. Investors have become accustomed to hearing about trillion-dollar opportunities and soaring demand for AI infrastructure. 

Yet every dollar poured into one corner of the economy is a dollar that cannot be spent elsewhere. That hidden tradeoff is beginning to show up in corporate earnings, creating an economy of AI haves and have-nots that could shape investment returns for years.

AI’s Biggest Winners Keep Pulling Further Ahead The contrast became clearer this week. Taiwan Semiconductor Manufacturing (NYSE:TSM | TSM Price Prediction) preannounced second-quarter revenue yesterday that climbed sharply from a year ago, capping another quarter fueled by insatiable AI chip demand. According to the company’s monthly revenue release, June sales reached another record, putting TSM on pace to report another quarter of record earnings when it reports results on Thursday.

That should surprise no one. TSM manufactures the advanced processors used by Nvidia (NASDAQ:NVDA), Advanced Micro Devices (NASDAQ:AMD), Broadcom (NASDAQ:AVGO), Apple (NASDAQ:AAPL), and many of the world’s largest semiconductor companies. As hyperscalers continue spending hundreds of billions of dollars on AI infrastructure, TSM remains one of the biggest beneficiaries.

The same trend is evident throughout the semiconductor ecosystem. Micron Technology (NASDAQ:MU) recently reported record profits as demand for high-bandwidth memory (HBM) continues to outstrip supply, while equipment makers supplying chip fabrication plants have enjoyed years of expanding order books.

These companies occupy the center of the AI spending universe, where nearly every additional dollar of capital expenditure eventually lands.

The AI boom isn't lifting all boats—it's siphoning capital from the rest of the tech world. Uncover the hidden 'Broken Window' effect creating a brutal divide between market winners and losers. © 24/7 Wall St. IBM Shows the Other Side of the AI Boom Conversely, IBM (NYSE:IBM) offered a glimpse of what happens outside that circle.

The company also just preannounced second-quarter results ahead of earnings, and while management continues highlighting growth in its AI business and the rollout of its new Z17 mainframe, another trend stood out. According to IBM’s letter to shareholders, its Infrastructure segment posted a 7% year-over-year sales decline, while profits also moved lower.

Ironically, IBM isn’t losing because customers have stopped investing in technology. It is because they’re investing almost exclusively in AI.

July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.

Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.

With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.

Companies have finite capital budgets. Servers packed with Nvidia GPUs, networking gear, storage arrays, and new data centers are consuming enormous portions of enterprise spending. That leaves fewer dollars available for upgrading legacy infrastructure, expanding traditional IT projects, or refreshing systems that aren’t viewed as mission-critical for AI deployment.

That resembles the economic lesson French economist Frederic Bastiat illustrated in his famous “broken window” parable. The spending everyone sees on replacing a broken window creates obvious winners — the glazier, who replaces the window — but the opportunities sacrificed elsewhere often remain invisible — the baker, cobbler, the bookseller that the shopkeeper would have spent his money at. 

AI infrastructure is producing the same effect: It is creating enormous wealth for semiconductor companies, while quietly delaying investment across other industries.

Investors Should Watch for a Growing Divide Second-quarter earnings season could become a turning point. If chipmakers, memory suppliers, and equipment manufacturers continue posting record results while companies further removed from AI infrastructure report slowing demand, investors will have fresh evidence that AI’s benefits remain heavily concentrated.

Granted, this imbalance won’t last forever. As AI infrastructure matures and capital spending eventually moderates, money should begin flowing back into software, enterprise systems, and other technology categories. But most Wall Street forecasts suggest that transition remains several years away.

Key Takeaway In short, investors shouldn’t assume every technology company benefits equally from the AI boom. The biggest winners today remain those selling the picks and shovels — chips, memory, manufacturing capacity, networking equipment, and power infrastructure. Companies operating farther down the technology stack may continue facing headwinds as enterprise budgets remain concentrated on AI buildouts. 

Understanding where capital is flowing — and just as importantly, where it isn’t — may prove to be one of the most valuable investing lessons of this AI cycle.

Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.

Over 50,000 people already have, along with global giants like General Motors and POSCO.

Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.

Contact [email protected] for any questions or corrections.
2026-07-14 16:12 27d ago
2026-07-14 10:30 27d ago
Is Broadcom Inc. (AVGO) a Buy as Wall Street Analysts Look Optimistic?
AVGO Broadcom
FMP Stock News
Original source text
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Let's take a look at what these Wall Street heavyweights have to say about Broadcom Inc. (AVGO - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Broadcom Inc. currently has an average brokerage recommendation (ABR) of 1.35, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 43 brokerage firms. An ABR of 1.35 approximates between Strong Buy and Buy.

Of the 43 recommendations that derive the current ABR, 34 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 79.1% and 7% of all recommendations.

Brokerage Recommendation Trends for AVGO

Check price target & stock forecast for Broadcom Inc. here>>>

The ABR suggests buying Broadcom Inc., but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Should You Invest in AVGO?Looking at the earnings estimate revisions for Broadcom Inc., the Zacks Consensus Estimate for the current year has increased 0% over the past month to $11.73.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Broadcom Inc. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Broadcom Inc may serve as a useful guide for investors.
2026-07-14 16:11 27d ago
2026-07-14 11:06 27d ago
The Charles Schwab Corporation (SCHW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
SCHW Charles Schwab
FMP Stock News
Original source text
Wall Street expects a year-over-year increase in earnings on higher revenues when The Charles Schwab Corporation (SCHW - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 21. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis company is expected to post quarterly earnings of $1.52 per share in its upcoming report, which represents a year-over-year change of +33.3%.

Revenues are expected to be $6.75 billion, up 15.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 2.25% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Charles Schwab?For Charles Schwab, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.30%.

On the other hand, the stock currently carries a Zacks Rank of #1.

So, this combination indicates that Charles Schwab will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Charles Schwab would post earnings of $1.39 per share when it actually produced earnings of $1.43, delivering a surprise of +2.88%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Charles Schwab appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
2026-07-14 16:11 27d ago
2026-07-14 10:51 27d ago
Fastenal (FAST) is a Top-Ranked Momentum Stock: Should You Buy?
FAST Fastenal
FMP Stock News
Original source text
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Fastenal (FAST - Free Report) Based in Winona, MN, Fastenal Company is a national wholesale distributor of industrial and construction supplies. The company distributes its products through a network of about 1,600 branch locations in North America.

FAST is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Industrial Products stock. FAST has a Momentum Style Score of A, and shares are up 2.1% over the past four weeks.

Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $1.24 per share. FAST boasts an average earnings surprise of +0.1%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, FAST should be on investors' short list.